<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med Inform Decis Mak</journal-id><journal-title>BMC Medical Informatics and Decision Making</journal-title><issn pub-type="epub">1472-6947</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">16539706</article-id><article-id pub-id-type="pmc">1431518</article-id><article-id pub-id-type="publisher-id">1472-6947-6-15</article-id><article-id pub-id-type="doi">10.1186/1472-6947-6-15</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>A Markov computer simulation model of the economics of neuromuscular blockade in patients with acute respiratory distress syndrome</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Macario</surname><given-names>Alex</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>amaca@stanford.edu</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Chow</surname><given-names>John L</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>jchow_y2k@yahoo.com</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Dexter</surname><given-names>Franklin</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>franklin-dexter@uiowa.edu</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Anesthesia, Stanford University School of Medicine, Stanford, CA 94305, USA</aff><aff id="I2"><label>2</label>Health Research &amp; Policy, Stanford University School of Medicine, Stanford, CA 94305, USA</aff><aff id="I3"><label>3</label>Division of Management Consulting, Department of Anesthesia, University of Iowa, Iowa City, Iowa, 52242, USA</aff><pub-date pub-type="collection"><year>2006</year></pub-date><pub-date pub-type="epub"><day>15</day><month>3</month><year>2006</year></pub-date><volume>6</volume><fpage>15</fpage><lpage>15</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1472-6947/6/15"></ext-link><history><date date-type="received"><day>9</day><month>5</month><year>2005</year></date><date date-type="accepted"><day>15</day><month>3</month><year>2006</year></date></history><permissions><copyright-statement>Copyright © 2006 Macario et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2006</copyright-year><copyright-holder>Macario et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"></ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><sec><title><offsets xml_i="3209" xml_f="3219" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="3230" xml_f="3929" txt_i="22" txt_f="721">Management of acute respiratory distress syndrome (ARDS) in the intensive care unit (ICU) is clinically challenging and costly. Neuromuscular blocking agents may facilitate mechanical ventilation and improve oxygenation, but may result in prolonged recovery of neuromuscular function and acute quadriplegic myopathy syndrome (AQMS). The goal of this study was to address a hypothetical question via computer modeling: Would a reduction in intubation time of 6 hours and/or a reduction in the incidence of AQMS from 25% to 21%, provide enough benefit to justify a drug with an additional expenditure of $267 (the difference in acquisition cost between a generic and brand name neuromuscular blocker)?</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="3970" xml_f="3977" txt_i="723" txt_f="730">Methods</offsets></title><p><offsets xml_i="3988" xml_f="4336" txt_i="731" txt_f="1079">The base case was a 55 year-old man in the ICU with ARDS who receives neuromuscular blockade for 3.5 days. A Markov model was designed with hypothetical patients in 1 of 6 mutually exclusive health states: ICU-intubated, ICU-extubated, hospital ward, long-term care, home, or death, over a period of 6 months. The net monetary benefit was computed.</offsets></p></sec><sec><title><offsets xml_i="4358" xml_f="4365" txt_i="1081" txt_f="1088">Results</offsets></title><p><offsets xml_i="4376" xml_f="4793" txt_i="1089" txt_f="1506">Our computer simulation modeling predicted the mean cost for ARDS patients receiving standard care for 6 months to be $62,238 (5% – 95% percentiles $42,259 – $83,766), with an overall 6-month mortality of 39%. Assuming a ceiling ratio of $35,000, even if a drug (that cost $267 more) hypothetically reduced AQMS from 25% to 21% and decreased intubation time by 6 hours, the net monetary benefit would only equal $137.</offsets></p></sec><sec><title><offsets xml_i="4815" xml_f="4825" txt_i="1508" txt_f="1518">Conclusion</offsets></title><p><offsets xml_i="4836" xml_f="5292" txt_i="1519" txt_f="1975">ARDS patients receiving a neuromuscular blocker have a high mortality, and unpredictable outcome, which results in large variability in costs per case. If a patient dies, there is no benefit to any drug that reduces ventilation time or AQMS incidence. A prospective, randomized pharmacoeconomic study of neuromuscular blockers in the ICU to asses AQMS or intubation times is impractical because of the highly variable clinical course of patients with ARDS.</offsets></p></sec></abstract></article-meta></front><body><sec><title><offsets xml_i="5354" xml_f="5364" txt_i="1984" txt_f="1994">Background</offsets></title><p><offsets xml_i="5375" xml_f="5517" txt_i="1995" txt_f="2137">Management of patients with acute respiratory distress syndrome (ARDS) in the intensive care unit (ICU) is clinically challenging and costly [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="5548" xml_f="5549" txt_i="2137" txt_f="2138">1</offsets></xref><offsets xml_i="5556" xml_f="5824" txt_i="2138" txt_f="2406">]. In ARDS patients with refractory hypoxemia, neuromuscular blocking agents may facilitate mechanical ventilation and improve oxygenation. However, prolonged recovery of neuromuscular function and development of acute quadriplegic myopathy syndrome (AQMS) can occur [</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="5855" xml_f="5856" txt_i="2406" txt_f="2407">2</offsets></xref><offsets xml_i="5863" xml_f="6036" txt_i="2407" txt_f="2580">]. While a variety of neuromuscular blockers have been utilized, it remains unclear which agent provides the optimal clinical benefit relative to the drug acquisition cost [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="6067" xml_f="6068" txt_i="2580" txt_f="2581">3</offsets></xref><offsets xml_i="6075" xml_f="6267" txt_i="2581" txt_f="2773">]. For example, using average wholesale prices, the cost of treating an ARDS patient with cisatracurium for 3.5 days is approximately $267 more than if the patient received vecuronium. (Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="6299" xml_f="6300" txt_i="2773" txt_f="2774">1</offsets></xref><offsets xml_i="6307" xml_f="6312" txt_i="2774" txt_f="2779"> and </offsets><xref ref-type="table" rid="T2"><offsets xml_i="6344" xml_f="6345" txt_i="2779" txt_f="2780">2</offsets></xref><offsets xml_i="6352" xml_f="6353" txt_i="2780" txt_f="2781">)</offsets></p><table-wrap position="float" id="T1"><label><offsets xml_i="6401" xml_f="6408" txt_i="2782" txt_f="2789">Table 1</offsets></label><caption><p><offsets xml_i="6428" xml_f="6530" txt_i="2789" txt_f="2891">Drug acquisition costs for 3.5 day cycle of neuromuscular blockade using average wholesale price (AWP)</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center"><offsets xml_i="6620" xml_f="6629" txt_i="2893" txt_f="2902">Load (mg)</offsets></td><td align="center"><offsets xml_i="6653" xml_f="6672" txt_i="2903" txt_f="2922">Mg infusion rate/hr</offsets></td><td align="center"><offsets xml_i="6696" xml_f="6708" txt_i="2923" txt_f="2935">AWP vial ($)</offsets></td><td align="center"><offsets xml_i="6732" xml_f="6746" txt_i="2936" txt_f="2950">Vial size (mg)</offsets></td><td align="center"><offsets xml_i="6770" xml_f="6781" txt_i="2951" txt_f="2962">Cost/mg ($)</offsets></td><td align="center"><offsets xml_i="6805" xml_f="6818" txt_i="2963" txt_f="2976">Load cost ($)</offsets></td><td align="center"><offsets xml_i="6842" xml_f="6865" txt_i="2977" txt_f="3000">Cycle infusion cost ($)</offsets></td><td align="center"><offsets xml_i="6889" xml_f="6903" txt_i="3001" txt_f="3015">Daily cost ($)</offsets></td><td align="center"><bold><offsets xml_i="6933" xml_f="6957" txt_i="3016" txt_f="3040">Total cost per cycle ($)</offsets></bold></td><td align="center"><offsets xml_i="6988" xml_f="6997" txt_i="3041" txt_f="3050">Total mgs</offsets></td><td align="center"><offsets xml_i="7021" xml_f="7033" txt_i="3051" txt_f="3063">Opened vials</offsets></td><td align="center"><offsets xml_i="7057" xml_f="7097" txt_i="3064" txt_f="3104">Total cost per cycle with open vials ($)</offsets></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="7143" xml_f="7153" txt_i="3105" txt_f="3115">Vecuronium</offsets></td><td align="center"><offsets xml_i="7177" xml_f="7178" txt_i="3116" txt_f="3117">7</offsets></td><td align="center"><offsets xml_i="7202" xml_f="7203" txt_i="3118" txt_f="3119">4</offsets></td><td align="center"><offsets xml_i="7227" xml_f="7231" txt_i="3120" txt_f="3124">9.69</offsets></td><td align="center"><offsets xml_i="7255" xml_f="7257" txt_i="3125" txt_f="3127">10</offsets></td><td align="center"><offsets xml_i="7281" xml_f="7285" txt_i="3128" txt_f="3132">0.97</offsets></td><td align="center"><offsets xml_i="7309" xml_f="7313" txt_i="3133" txt_f="3137">6.78</offsets></td><td align="center"><offsets xml_i="7337" xml_f="7340" txt_i="3138" txt_f="3141">326</offsets></td><td align="center"><offsets xml_i="7364" xml_f="7366" txt_i="3142" txt_f="3144">93</offsets></td><td align="center"><bold><offsets xml_i="7396" xml_f="7399" txt_i="3145" txt_f="3148">332</offsets></bold></td><td align="center"><offsets xml_i="7430" xml_f="7433" txt_i="3149" txt_f="3152">343</offsets></td><td align="center"><offsets xml_i="7457" xml_f="7459" txt_i="3153" txt_f="3155">35</offsets></td><td align="center"><offsets xml_i="7483" xml_f="7486" txt_i="3156" txt_f="3159">339</offsets></td></tr><tr><td align="left"><offsets xml_i="7517" xml_f="7530" txt_i="3160" txt_f="3173">Cisatracurium</offsets></td><td align="center"><offsets xml_i="7554" xml_f="7556" txt_i="3174" txt_f="3176">14</offsets></td><td align="center"><offsets xml_i="7580" xml_f="7581" txt_i="3177" txt_f="3178">8</offsets></td><td align="center"><offsets xml_i="7605" xml_f="7610" txt_i="3179" txt_f="3184">174.5</offsets></td><td align="center"><offsets xml_i="7634" xml_f="7637" txt_i="3185" txt_f="3188">200</offsets></td><td align="center"><offsets xml_i="7661" xml_f="7665" txt_i="3189" txt_f="3193">0.87</offsets></td><td align="center"><offsets xml_i="7689" xml_f="7694" txt_i="3194" txt_f="3199">12.22</offsets></td><td align="center"><offsets xml_i="7718" xml_f="7721" txt_i="3200" txt_f="3203">586</offsets></td><td align="center"><offsets xml_i="7745" xml_f="7748" txt_i="3204" txt_f="3207">168</offsets></td><td align="center"><bold><offsets xml_i="7778" xml_f="7781" txt_i="3208" txt_f="3211">599</offsets></bold></td><td align="center"><offsets xml_i="7812" xml_f="7815" txt_i="3212" txt_f="3215">686</offsets></td><td align="center"><offsets xml_i="7839" xml_f="7840" txt_i="3216" txt_f="3217">4</offsets></td><td align="center"><offsets xml_i="7864" xml_f="7867" txt_i="3218" txt_f="3221">698</offsets></td></tr><tr><td align="left"><offsets xml_i="7898" xml_f="7915" txt_i="3222" txt_f="3239">Cost difference =</offsets></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td align="center"><bold><offsets xml_i="8017" xml_f="8022" txt_i="3248" txt_f="3253">$ 267</offsets></bold></td><td></td><td></td><td align="center"><offsets xml_i="8071" xml_f="8076" txt_i="3256" txt_f="3261">$ 359</offsets></td></tr></tbody></table></table-wrap><table-wrap position="float" id="T2"><label><offsets xml_i="8159" xml_f="8166" txt_i="3262" txt_f="3269">Table 2</offsets></label><caption><p><offsets xml_i="8186" xml_f="8280" txt_i="3269" txt_f="3363">Drug acquisition costs for 3.5 day cycle of neuromuscular blockade using average selling price</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center"><offsets xml_i="8370" xml_f="8379" txt_i="3365" txt_f="3374">Load (mg)</offsets></td><td align="center"><offsets xml_i="8403" xml_f="8422" txt_i="3375" txt_f="3394">Mg infusion rate/hr</offsets></td><td align="center"><offsets xml_i="8446" xml_f="8466" txt_i="3395" txt_f="3415">Mean sales price ($)</offsets></td><td align="center"><offsets xml_i="8490" xml_f="8504" txt_i="3416" txt_f="3430">Vial size (mg)</offsets></td><td align="center"><offsets xml_i="8528" xml_f="8539" txt_i="3431" txt_f="3442">Cost/mg ($)</offsets></td><td align="center"><offsets xml_i="8563" xml_f="8576" txt_i="3443" txt_f="3456">Load cost ($)</offsets></td><td align="center"><offsets xml_i="8600" xml_f="8623" txt_i="3457" txt_f="3480">Cycle infusion cost ($)</offsets></td><td align="center"><offsets xml_i="8647" xml_f="8661" txt_i="3481" txt_f="3495">Daily cost ($)</offsets></td><td align="center"><bold><offsets xml_i="8691" xml_f="8715" txt_i="3496" txt_f="3520">Total cost per cycle ($)</offsets></bold></td><td align="center"><offsets xml_i="8746" xml_f="8755" txt_i="3521" txt_f="3530">Total mgs</offsets></td><td align="center"><offsets xml_i="8779" xml_f="8791" txt_i="3531" txt_f="3543">Opened vials</offsets></td><td align="center"><offsets xml_i="8815" xml_f="8855" txt_i="3544" txt_f="3584">Total cost per cycle with open vials ($)</offsets></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="8901" xml_f="8911" txt_i="3585" txt_f="3595">Vecuronium</offsets></td><td align="center"><offsets xml_i="8935" xml_f="8936" txt_i="3596" txt_f="3597">7</offsets></td><td align="center"><offsets xml_i="8960" xml_f="8961" txt_i="3598" txt_f="3599">4</offsets></td><td align="center"><offsets xml_i="8985" xml_f="8989" txt_i="3600" txt_f="3604">3.58</offsets></td><td align="center"><offsets xml_i="9013" xml_f="9015" txt_i="3605" txt_f="3607">10</offsets></td><td align="center"><offsets xml_i="9039" xml_f="9043" txt_i="3608" txt_f="3612">0.36</offsets></td><td align="center"><offsets xml_i="9067" xml_f="9070" txt_i="3613" txt_f="3616">2.5</offsets></td><td align="center"><offsets xml_i="9094" xml_f="9097" txt_i="3617" txt_f="3620">120</offsets></td><td align="center"><offsets xml_i="9121" xml_f="9123" txt_i="3621" txt_f="3623">34</offsets></td><td align="center"><bold><offsets xml_i="9153" xml_f="9156" txt_i="3624" txt_f="3627">123</offsets></bold></td><td align="center"><offsets xml_i="9187" xml_f="9190" txt_i="3628" txt_f="3631">343</offsets></td><td align="center"><offsets xml_i="9214" xml_f="9216" txt_i="3632" txt_f="3634">35</offsets></td><td align="center"><offsets xml_i="9240" xml_f="9243" txt_i="3635" txt_f="3638">125</offsets></td></tr><tr><td align="left"><offsets xml_i="9274" xml_f="9287" txt_i="3639" txt_f="3652">Cisatracurium</offsets></td><td align="center"><offsets xml_i="9311" xml_f="9313" txt_i="3653" txt_f="3655">14</offsets></td><td align="center"><offsets xml_i="9337" xml_f="9338" txt_i="3656" txt_f="3657">8</offsets></td><td align="center"><offsets xml_i="9362" xml_f="9367" txt_i="3658" txt_f="3663">119.5</offsets></td><td align="center"><offsets xml_i="9391" xml_f="9394" txt_i="3664" txt_f="3667">200</offsets></td><td align="center"><offsets xml_i="9418" xml_f="9422" txt_i="3668" txt_f="3672">0.60</offsets></td><td align="center"><offsets xml_i="9446" xml_f="9449" txt_i="3673" txt_f="3676">8.4</offsets></td><td align="center"><offsets xml_i="9473" xml_f="9476" txt_i="3677" txt_f="3680">402</offsets></td><td align="center"><offsets xml_i="9500" xml_f="9503" txt_i="3681" txt_f="3684">115</offsets></td><td align="center"><bold><offsets xml_i="9533" xml_f="9536" txt_i="3685" txt_f="3688">410</offsets></bold></td><td align="center"><offsets xml_i="9567" xml_f="9570" txt_i="3689" txt_f="3692">686</offsets></td><td align="center"><offsets xml_i="9594" xml_f="9595" txt_i="3693" txt_f="3694">4</offsets></td><td align="center"><offsets xml_i="9619" xml_f="9622" txt_i="3695" txt_f="3698">478</offsets></td></tr><tr><td align="center"><offsets xml_i="9655" xml_f="9672" txt_i="3699" txt_f="3716">Cost difference =</offsets></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td align="center"><bold><offsets xml_i="9774" xml_f="9779" txt_i="3725" txt_f="3730">$ 287</offsets></bold></td><td></td><td></td><td align="center"><offsets xml_i="9828" xml_f="9833" txt_i="3733" txt_f="3738">$ 353</offsets></td></tr></tbody></table></table-wrap><p><offsets xml_i="9875" xml_f="10557" txt_i="3739" txt_f="4421">Assessing the clinical and economic consequences of pharmacological interventions in ARDS patients is difficult. The reasons include a heterogeneous patient population, a wide range of supportive interventions, and complex causes of the patient's condition. For example, to conduct a clinical trial with sufficient statistical power to detect a 10% absolute decrease in the incidence of AQMS, a randomized clinical trial would have to enroll 800 patients in each of the two groups, assuming censoring due to mortality is 30%. In such situations where clinical studies are expensive and complicated to complete, computer modeling is an appropriate initial approach to yield insights.</offsets></p><p><offsets xml_i="10564" xml_f="10841" txt_i="4422" txt_f="4699">The goal of this study was to address a hypothetical question via computer modeling: Would a reduction in intubation time of 6 hours and/or a reduction in the incidence AQMS from 25% to 21% in ARDS patients, provide enough benefit to justify an additional expenditure of $267 [</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="10872" xml_f="10873" txt_i="4699" txt_f="4700">2</offsets></xref><offsets xml_i="10880" xml_f="10881" txt_i="4700" txt_f="4701">,</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="10912" xml_f="10913" txt_i="4701" txt_f="4702">4</offsets></xref><offsets xml_i="10920" xml_f="10922" txt_i="4702" txt_f="4704">]?</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="10963" xml_f="10970" txt_i="4706" txt_f="4713">Methods</offsets></title><sec><title><offsets xml_i="10990" xml_f="11016" txt_i="4714" txt_f="4740">Overview of computer model</offsets></title><p><offsets xml_i="11027" xml_f="11414" txt_i="4741" txt_f="5128">The numerator in the incremental cost-effectiveness ratio takes into consideration the additional costs that one intervention imposes over another. The denominator considers the incremental improvement in health related quality of life calculated as quality-adjusted life-years (QALY). Both costs and QALYs need to be considered together, otherwise death becomes the least costly option.</offsets></p><p><offsets xml_i="11421" xml_f="11816" txt_i="5129" txt_f="5524">Using the results of our literature review, we simulated the rates of healing and complications associated with patients with ARDS, computed associated incremental costs, assumed a societal perspective for the analysis as recommended by an expert panel, estimated quality of life for relevant health states, and performed a sensitivity analysis to evaluate the impact of changing key variables [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="11847" xml_f="11848" txt_i="5524" txt_f="5525">5</offsets></xref><offsets xml_i="11855" xml_f="11857" txt_i="5525" txt_f="5527">].</offsets></p><sec><title><offsets xml_i="11873" xml_f="11885" txt_i="5528" txt_f="5540">Markov model</offsets></title><p><offsets xml_i="11896" xml_f="12677" txt_i="5541" txt_f="6322">Conventional models based on decision trees are limited in their ability to describe events that can occur multiple times in the care of a patient (e.g., ICU readmissions). A Markov model is a mathematical representation of patients in a series of health states. Such a model provides a tool to deal with multiple clinical uncertainties because the study can be repeated in successive iterations by varying parameters to address "What if?" questions. The use of Markov models is particular relevant in the ICU settings given the constantly changing nature of the patients' disease conditions and treatments. This methodology has been applied successfully in studying the incidence of nosocomial infections in critically ill patients, and the mortality of ICU patients with sepsis [</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="12708" xml_f="12709" txt_i="6322" txt_f="6323">6</offsets></xref><offsets xml_i="12716" xml_f="12717" txt_i="6323" txt_f="6324">,</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="12748" xml_f="12749" txt_i="6324" txt_f="6325">7</offsets></xref><offsets xml_i="12756" xml_f="12758" txt_i="6325" txt_f="6327">].</offsets></p></sec><sec><title><offsets xml_i="12780" xml_f="12789" txt_i="6329" txt_f="6338">Base case</offsets></title><p><offsets xml_i="12800" xml_f="13237" txt_i="6339" txt_f="6776">For our study, we chose the following base case; a 55 year-old man is admitted to the ICU because of ARDS secondary to pneumonia (pneumonia sepsis is the most common etiology for ARDS and receives neuromuscular blockade for 3.5 days. These hypothetical patients were modeled to be in 1 of 6 mutually exclusive health states: ICU-intubated, ICU-extubated, hospital ward, long-term care, home, or death, over a period of 6 months. (Figure </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="13267" xml_f="13268" txt_i="6776" txt_f="6777">1</offsets></xref><offsets xml_i="13275" xml_f="13276" txt_i="6777" txt_f="6778">)</offsets></p><fig position="float" id="F1"><label><offsets xml_i="13317" xml_f="13325" txt_i="6779" txt_f="6787">Figure 1</offsets></label><caption><p><bold><offsets xml_i="13351" xml_f="13418" txt_i="6787" txt_f="6854">Markov model for patient with ARDS receiving neuromuscular blockade</offsets></bold><offsets xml_i="13425" xml_f="13558" txt_i="6854" txt_f="6987">. Simulated patients were classified into 6 health states. Patient progression was divided into 3.5-day cycles over a 6-month period.</offsets></p></caption><graphic xlink:href="1472-6947-6-15-1"></graphic></fig><p><offsets xml_i="13630" xml_f="13997" txt_i="6988" txt_f="7355">A 3.5-day cycle time was chosen because it approximates the time of important clinical changes. Six months was chosen because it allows the model to consider the natural progression and resolution of the disease over a reasonable time frame. We also modeled a 1-month period. Choosing a longer period such as 12 or 24 months period would have been unnecessarily long.</offsets></p></sec><sec><title><offsets xml_i="14019" xml_f="14039" txt_i="7357" txt_f="7377">Net monetary benefit</offsets></title><p><offsets xml_i="14050" xml_f="14174" txt_i="7378" txt_f="7502">The incremental cost-effectiveness ratio has poor statistical properties within the range of values relevant to this study [</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="14205" xml_f="14206" txt_i="7502" txt_f="7503">8</offsets></xref><offsets xml_i="14213" xml_f="15253" txt_i="7503" txt_f="8543">]. If two drugs provide similar effectiveness, then trying to calculate the incremental cost-effectiveness ratio results in division by zero. Difficulties arise in how to place a monetary value on a clinical improvement. This valuation is performed by assigning a monetary value to a unit of effectiveness (Z), and multiplying it by the net number of units of effectiveness achieved. The value Z represents the maximum amount that society would be willing to pay for the incremental improvement in outcome (and therefore its maximum value). Medical interventions with a cost-effectiveness of less than $35,000 (Z) per QALY are generally considered to represent acceptable value for money, i.e., be cost-effective. As there is no correct or well-accepted value of Z for a given clinical improvement, we tested a range of Z values from 0 to $100,000. The net monetary benefit addresses these concerns by assigning a monetary value to the incremental benefit achieved, and subtracting from this the incremental cost of achieving this benefit [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="15284" xml_f="15285" txt_i="8543" txt_f="8544">9</offsets></xref><offsets xml_i="15292" xml_f="15294" txt_i="8544" txt_f="8546">].</offsets></p><p><offsets xml_i="15301" xml_f="15576" txt_i="8547" txt_f="8822">A positive net monetary benefit implies that the cost of a new therapy is less than the value of the additional benefit achieved. A negative net monetary benefit implies that an intervention should be rejected, as its costs are higher than the value of the benefit achieved [</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="15608" xml_f="15610" txt_i="8822" txt_f="8824">10</offsets></xref><offsets xml_i="15617" xml_f="15619" txt_i="8824" txt_f="8826">].</offsets></p></sec><sec><title><offsets xml_i="15641" xml_f="15690" txt_i="8828" txt_f="8877">Hospital costs and health related quality of life</offsets></title><p><offsets xml_i="15701" xml_f="16275" txt_i="8878" txt_f="9452">Total hospital costs can be separated into fixed (which do not change in proportion to the number of ICU cases) and variable components. For example, from the facility's perspective, nursing care time may be considered a fixed cost, as staff is paid regardless of whether there is one more or one less ICU patient. However, we assumed that having a provider take care of an ARDS patient is an incremental cost to society, as is commonly done in cost-effectiveness studies, to reflect that, from society's point of view, there is a cost for the provider's time and expertise.</offsets></p><p><offsets xml_i="16282" xml_f="16595" txt_i="9453" txt_f="9766">Using data gathered from the literature and utilizing a "bottom up" cost methodology, we estimated direct medical costs per day as the hypothetical patients progressed thru the various health states. We assumed that 10% of the costs assigned to any of the health states are for physicians' professional services [</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="16627" xml_f="16629" txt_i="9766" txt_f="9768">11</offsets></xref><offsets xml_i="16636" xml_f="16793" txt_i="9768" txt_f="9925">]. We assumed that daily costs in any of the health states are linear, meaning that the first ICU day, for example, is equally costly as subsequent ICU days.</offsets></p><p><offsets xml_i="16800" xml_f="17406" txt_i="9926" txt_f="10532">Quality-adjusted life-years include a length of time component (e.g., one year) and a quality of life component (i.e., utility). Health utility is the numerical valuation of one's health-related quality of life on a linear scale from 0.00 (death) to 1.00 (perfect health). For example, one quality-adjusted life-year for an individual in perfect health (with a utility = 1.0) for one year (QALY = 1) is considered equivalent to two years in a health state with utility = 0.5. (QALY = 1). The advantage of using QALYs is that they combine number of years saved as well as the quality of life of those years.</offsets></p><p><offsets xml_i="17413" xml_f="17528" txt_i="10533" txt_f="10648">Directly ascertaining utilities in critically ill patients is done infrequently and is methodologically difficult [</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="17560" xml_f="17562" txt_i="10648" txt_f="10650">12</offsets></xref><offsets xml_i="17569" xml_f="17688" txt_i="10650" txt_f="10769">]. Published utilities from subgroups of ICU patients have been confirmed with the EuroQol scale and the Rosser index [</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="17720" xml_f="17722" txt_i="10769" txt_f="10771">13</offsets></xref><offsets xml_i="17729" xml_f="17730" txt_i="10771" txt_f="10772">-</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="17762" xml_f="17764" txt_i="10772" txt_f="10774">15</offsets></xref><offsets xml_i="17771" xml_f="17797" txt_i="10774" txt_f="10800">]. Patients in the EuroQol</offsets><sup><offsets xml_i="17802" xml_f="17804" txt_i="10800" txt_f="10802">© </offsets></sup><offsets xml_i="17810" xml_f="17855" txt_i="10802" txt_f="10847">EQ-5D scale are classified into one of 243 (3</offsets><sup><offsets xml_i="17860" xml_f="17861" txt_i="10847" txt_f="10848">5</offsets></sup><offsets xml_i="17867" xml_f="17934" txt_i="10848" txt_f="10915">) health states (mobility, self-care, usual activity, pain, mood) [</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="17966" xml_f="17968" txt_i="10915" txt_f="10917">16</offsets></xref><offsets xml_i="17975" xml_f="18483" txt_i="10917" txt_f="11425">]. Each state is scored from 1 (normal) to 3 (the most impaired). For example, a mobility score of "1" indicates "no problems in walking about," while a "3" is "confined to bed." The scores for the five states can be assigned a utility valuation from the general public. For example, a EuroQol mobility (3), self-care (3), usual activity (3), pain (2), mood (1) signifies a utility of 0.08. In contrast, EuroQol mobility (1), self-care (1), usual activity (2), pain (1), mood (2) signifies a utility of 0.65.</offsets></p><p><offsets xml_i="18490" xml_f="18737" txt_i="11426" txt_f="11673">In the Rosser classification of illness, assigning levels of disability and distress to each health state determine the quality of life of a patient. For example, Rosser Disability level VII with Distress level B (mild) indicates a utility of 0.8.</offsets></p><p><offsets xml_i="18744" xml_f="18921" txt_i="11674" txt_f="11851">Since health values of seriously ill patients vary widely, we incorporated a wide range of quality of life for each health state, assuming no state was worse than death. (Table </offsets><xref ref-type="table" rid="T3"><offsets xml_i="18953" xml_f="18954" txt_i="11851" txt_f="11852">3</offsets></xref><offsets xml_i="18961" xml_f="18962" txt_i="11852" txt_f="11853">)</offsets></p><table-wrap position="float" id="T3"><label><offsets xml_i="19010" xml_f="19017" txt_i="11854" txt_f="11861">Table 3</offsets></label><caption><p><offsets xml_i="19037" xml_f="19105" txt_i="11861" txt_f="11929">Costs and utilities used for each health state for computer modeling</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><offsets xml_i="19184" xml_f="19196" txt_i="11930" txt_f="11942">Health state</offsets></td><td align="center"><offsets xml_i="19220" xml_f="19236" txt_i="11943" txt_f="11959">Cost per day ($)</offsets></td><td align="center" colspan="2"><offsets xml_i="19272" xml_f="19277" txt_i="11960" txt_f="11965">Range</offsets></td><td align="center"><offsets xml_i="19301" xml_f="19308" txt_i="11966" txt_f="11973">Utility</offsets></td><td align="center"><offsets xml_i="19332" xml_f="19337" txt_i="11974" txt_f="11979">Range</offsets></td></tr><tr><td></td><td></td><td align="center"><offsets xml_i="19388" xml_f="19395" txt_i="11982" txt_f="11989">Low ($)</offsets></td><td align="center"><offsets xml_i="19419" xml_f="19427" txt_i="11990" txt_f="11998">High ($)</offsets></td><td></td><td></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="19491" xml_f="19504" txt_i="12001" txt_f="12014">ICU intubated</offsets></td><td align="center"><offsets xml_i="19528" xml_f="19532" txt_i="12015" txt_f="12019">2200</offsets></td><td align="center"><offsets xml_i="19556" xml_f="19560" txt_i="12020" txt_f="12024">1400</offsets><sup><offsets xml_i="19565" xml_f="19570" txt_i="12024" txt_f="12029">24,25</offsets></sup></td><td align="center"><offsets xml_i="19600" xml_f="19604" txt_i="12030" txt_f="12034">3700</offsets><sup><offsets xml_i="19609" xml_f="19614" txt_i="12034" txt_f="12039">26,27</offsets></sup></td><td align="center"><offsets xml_i="19644" xml_f="19647" txt_i="12040" txt_f="12043">0.1</offsets></td><td align="center"><offsets xml_i="19671" xml_f="19680" txt_i="12044" txt_f="12053">0.08–0.15</offsets></td></tr><tr><td align="left"><offsets xml_i="19711" xml_f="19724" txt_i="12054" txt_f="12067">ICU extubated</offsets></td><td align="center"><offsets xml_i="19748" xml_f="19752" txt_i="12068" txt_f="12072">1500</offsets><sup><offsets xml_i="19757" xml_f="19759" txt_i="12072" txt_f="12074">28</offsets></sup></td><td align="center"><offsets xml_i="19789" xml_f="19792" txt_i="12075" txt_f="12078">700</offsets><sup><offsets xml_i="19797" xml_f="19799" txt_i="12078" txt_f="12080">29</offsets></sup></td><td align="center"><offsets xml_i="19829" xml_f="19833" txt_i="12081" txt_f="12085">2400</offsets></td><td align="center"><offsets xml_i="19857" xml_f="19860" txt_i="12086" txt_f="12089">0.2</offsets></td><td align="center"><offsets xml_i="19884" xml_f="19893" txt_i="12090" txt_f="12099">0.1 – 0.3</offsets></td></tr><tr><td align="left"><offsets xml_i="19924" xml_f="19937" txt_i="12100" txt_f="12113">Hospital ward</offsets></td><td align="center"><offsets xml_i="19961" xml_f="19964" txt_i="12114" txt_f="12117">700</offsets></td><td align="center"><offsets xml_i="19988" xml_f="19991" txt_i="12118" txt_f="12121">450</offsets><sup><offsets xml_i="19996" xml_f="20001" txt_i="12121" txt_f="12126">30,31</offsets></sup></td><td align="center"><offsets xml_i="20031" xml_f="20035" txt_i="12127" txt_f="12131">1700</offsets></td><td align="center"><offsets xml_i="20059" xml_f="20062" txt_i="12132" txt_f="12135">0.5</offsets></td><td align="center"><offsets xml_i="20086" xml_f="20095" txt_i="12136" txt_f="12145">0.25–0.56</offsets><sup><offsets xml_i="20100" xml_f="20102" txt_i="12145" txt_f="12147">32</offsets></sup></td></tr><tr><td align="left"><offsets xml_i="20139" xml_f="20153" txt_i="12148" txt_f="12162">Long term care</offsets></td><td align="center"><offsets xml_i="20177" xml_f="20180" txt_i="12163" txt_f="12166">350</offsets></td><td align="center"><offsets xml_i="20204" xml_f="20207" txt_i="12167" txt_f="12170">100</offsets><sup><offsets xml_i="20212" xml_f="20214" txt_i="12170" txt_f="12172">33</offsets></sup></td><td align="center"><offsets xml_i="20244" xml_f="20247" txt_i="12173" txt_f="12176">925</offsets></td><td align="center"><offsets xml_i="20271" xml_f="20275" txt_i="12177" txt_f="12181">0.65</offsets></td><td align="center"><offsets xml_i="20299" xml_f="20303" txt_i="12182" txt_f="12186">0.45</offsets><sup><offsets xml_i="20308" xml_f="20311" txt_i="12186" txt_f="12189">34 </offsets></sup><offsets xml_i="20317" xml_f="20323" txt_i="12189" txt_f="12195">– 0.77</offsets><sup><offsets xml_i="20328" xml_f="20333" txt_i="12195" txt_f="12200">35,36</offsets></sup></td></tr><tr><td align="left"><offsets xml_i="20370" xml_f="20374" txt_i="12201" txt_f="12205">Home</offsets></td><td align="center"><offsets xml_i="20398" xml_f="20399" txt_i="12206" txt_f="12207">0</offsets></td><td></td><td></td><td align="center"><offsets xml_i="20441" xml_f="20445" txt_i="12210" txt_f="12214">0.80</offsets></td><td align="center"><offsets xml_i="20469" xml_f="20473" txt_i="12215" txt_f="12219">0.78</offsets><sup><offsets xml_i="20478" xml_f="20481" txt_i="12219" txt_f="12222">37 </offsets></sup><offsets xml_i="20487" xml_f="20493" txt_i="12222" txt_f="12228">– 0.92</offsets><sup><offsets xml_i="20498" xml_f="20503" txt_i="12228" txt_f="12233">38,39</offsets></sup></td></tr></tbody></table></table-wrap></sec></sec><sec><title><offsets xml_i="20572" xml_f="20607" txt_i="12236" txt_f="12271">Question asked of computer modeling</offsets></title><p><offsets xml_i="20618" xml_f="21214" txt_i="12272" txt_f="12868">The computer modeling of the natural history of ARDS used incidences of progressing through the health states as estimated from the articles retrieved from the literature. We then asked the question, "Would a reduction in intubation time of 6 hours and/or a reduction in the incidence AQMS from 25% to 21% in ARDS patients, provide enough benefit to justify an additional expenditure of $267? Four scenarios were specifically considered (1) the agent reduces the incidence of myopathy from 25 to 21%, (2) the agent reduces the duration of mechanical ventilation by 6 hours, (3) both; (4) neither.</offsets></p></sec><sec><title><offsets xml_i="21236" xml_f="21256" txt_i="12870" txt_f="12890">Sensitivity analyses</offsets></title><p><offsets xml_i="21267" xml_f="21727" txt_i="12891" txt_f="13351">The probabilistic sensitivity analysis considered uncertainties in all probabilities, utilities, and costs simultaneously. Mean values for the net monetary benefit were calculated for results of N = 10,000 Monte-Carlo simulations (@Risk 4.0, Newfield, NY, Palisade Corporation). Triangular distributions were used for parameter values, with the mode being the base case and the 5th and 95th percentiles being the lower and upper limits of the ranges reported [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="21759" xml_f="21761" txt_i="13351" txt_f="13353">17</offsets></xref><offsets xml_i="21768" xml_f="21770" txt_i="13353" txt_f="13355">].</offsets></p><p><offsets xml_i="21777" xml_f="21907" txt_i="13356" txt_f="13486">All costs are reported in year 2004 U.S. dollars. We discounted all future costs and quality-adjusted life-years at 3% per annum [</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="21939" xml_f="21941" txt_i="13486" txt_f="13488">18</offsets></xref><offsets xml_i="21948" xml_f="21950" txt_i="13488" txt_f="13490">].</offsets></p></sec></sec><sec><title><offsets xml_i="21978" xml_f="21985" txt_i="13493" txt_f="13500">Results</offsets></title><p><offsets xml_i="21996" xml_f="22245" txt_i="13501" txt_f="13750">ARDS patients receiving a neuromuscular blocker have a high mortality, and unpredictable outcome, which results in large variability in costs per case. If a patient dies, there is no benefit to a drug that reduces ventilation time or AQMS incidence.</offsets></p><sec><title><offsets xml_i="22261" xml_f="22278" txt_i="13751" txt_f="13768">Computer modeling</offsets></title><p><offsets xml_i="22289" xml_f="22581" txt_i="13769" txt_f="14061">The estimated mean total cost for an ARDS patient receiving standard care for 6 months was $62,238 (5% – 95% percentiles $42,259 – $83,766; median, $61,885). Our computer model predicted that out of 100 hypothetical patients with ARDS, 39% would be expected to be dead after 6 months. (Table </offsets><xref ref-type="table" rid="T4"><offsets xml_i="22613" xml_f="22614" txt_i="14061" txt_f="14062">4</offsets></xref><offsets xml_i="22621" xml_f="22622" txt_i="14062" txt_f="14063">)</offsets></p><table-wrap position="float" id="T4"><label><offsets xml_i="22670" xml_f="22677" txt_i="14064" txt_f="14071">Table 4</offsets></label><caption><p><offsets xml_i="22697" xml_f="22765" txt_i="14071" txt_f="14139">Fraction of patients in each health state after 1 month and 6 months</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><underline><offsets xml_i="22855" xml_f="22867" txt_i="14140" txt_f="14152">Health state</offsets></underline></td><td align="center"><underline><offsets xml_i="22914" xml_f="22927" txt_i="14153" txt_f="14166">After 1 month</offsets></underline></td><td align="center"><underline><offsets xml_i="22974" xml_f="22988" txt_i="14167" txt_f="14181">After 6 months</offsets></underline></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="23046" xml_f="23059" txt_i="14182" txt_f="14195">ICU intubated</offsets></td><td align="center"><offsets xml_i="23083" xml_f="23086" txt_i="14196" txt_f="14199">28%</offsets></td><td align="center"><offsets xml_i="23110" xml_f="23112" txt_i="14200" txt_f="14202">6%</offsets></td></tr><tr><td align="left"><offsets xml_i="23143" xml_f="23156" txt_i="14203" txt_f="14216">ICU extubated</offsets></td><td align="center"><offsets xml_i="23180" xml_f="23183" txt_i="14217" txt_f="14220">23%</offsets></td><td align="center"><offsets xml_i="23207" xml_f="23209" txt_i="14221" txt_f="14223">6%</offsets></td></tr><tr><td align="left"><offsets xml_i="23240" xml_f="23253" txt_i="14224" txt_f="14237">Hospital ward</offsets></td><td align="center"><offsets xml_i="23277" xml_f="23279" txt_i="14238" txt_f="14240">9%</offsets></td><td align="center"><offsets xml_i="23303" xml_f="23305" txt_i="14241" txt_f="14243">4%</offsets></td></tr><tr><td align="left"><offsets xml_i="23336" xml_f="23359" txt_i="14244" txt_f="14267">Off site long term care</offsets></td><td align="center"><offsets xml_i="23383" xml_f="23385" txt_i="14268" txt_f="14270">9%</offsets></td><td align="center"><offsets xml_i="23409" xml_f="23412" txt_i="14271" txt_f="14274">18%</offsets></td></tr><tr><td align="left"><offsets xml_i="23443" xml_f="23447" txt_i="14275" txt_f="14279">Home</offsets></td><td align="center"><offsets xml_i="23471" xml_f="23473" txt_i="14280" txt_f="14282">8%</offsets></td><td align="center"><offsets xml_i="23497" xml_f="23500" txt_i="14283" txt_f="14286">28%</offsets></td></tr><tr><td align="left"><offsets xml_i="23531" xml_f="23535" txt_i="14287" txt_f="14291">Dead</offsets></td><td align="center"><offsets xml_i="23559" xml_f="23562" txt_i="14292" txt_f="14295">23%</offsets></td><td align="center"><offsets xml_i="23586" xml_f="23589" txt_i="14296" txt_f="14299">39%</offsets></td></tr></tbody></table></table-wrap><p><offsets xml_i="23631" xml_f="23674" txt_i="14300" txt_f="14343">Results of literature review are in Tables </offsets><xref ref-type="table" rid="T5"><offsets xml_i="23706" xml_f="23707" txt_i="14343" txt_f="14344">5</offsets></xref><offsets xml_i="23714" xml_f="23716" txt_i="14344" txt_f="14346">, </offsets><xref ref-type="table" rid="T6"><offsets xml_i="23748" xml_f="23749" txt_i="14346" txt_f="14347">6</offsets></xref><offsets xml_i="23756" xml_f="23758" txt_i="14347" txt_f="14349">, </offsets><xref ref-type="table" rid="T7"><offsets xml_i="23790" xml_f="23791" txt_i="14349" txt_f="14350">7</offsets></xref><offsets xml_i="23798" xml_f="23799" txt_i="14350" txt_f="14351">.</offsets></p><table-wrap position="float" id="T5"><label><offsets xml_i="23847" xml_f="23854" txt_i="14352" txt_f="14359">Table 5</offsets></label><caption><p><offsets xml_i="23874" xml_f="23943" txt_i="14359" txt_f="14428">Randomized control trials of treatments for ARDS published after 1998</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold><offsets xml_i="24028" xml_f="24034" txt_i="14429" txt_f="14435">Author</offsets></bold></td><td align="center"><bold><offsets xml_i="24071" xml_f="24077" txt_i="14436" txt_f="14442">Derdak</offsets></bold><sup><offsets xml_i="24089" xml_f="24091" txt_i="14442" txt_f="14444">40</offsets></sup></td><td align="center"><bold><offsets xml_i="24127" xml_f="24133" txt_i="14445" txt_f="14451">Eisner</offsets></bold><sup><offsets xml_i="24145" xml_f="24147" txt_i="14451" txt_f="14453">41</offsets></sup></td><td align="center"><bold><offsets xml_i="24183" xml_f="24192" txt_i="14454" txt_f="14463">Gattinoni</offsets></bold><sup><offsets xml_i="24204" xml_f="24206" txt_i="14463" txt_f="14465">42</offsets></sup></td><td align="center"><bold><offsets xml_i="24242" xml_f="24254" txt_i="14466" txt_f="14478">ARDS network</offsets></bold><sup><offsets xml_i="24266" xml_f="24268" txt_i="14478" txt_f="14480">43</offsets></sup></td><td align="center"><bold><offsets xml_i="24304" xml_f="24307" txt_i="14481" txt_f="14484">Ely</offsets></bold><sup><offsets xml_i="24319" xml_f="24321" txt_i="14484" txt_f="14486">44</offsets></sup></td><td align="center"><bold><offsets xml_i="24357" xml_f="24364" txt_i="14487" txt_f="14494">Lagneau</offsets></bold><sup><offsets xml_i="24376" xml_f="24378" txt_i="14494" txt_f="14496">45</offsets></sup></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="24430" xml_f="24438" txt_i="14497" txt_f="14505">Subjects</offsets></td><td align="center"><offsets xml_i="24462" xml_f="24477" txt_i="14506" txt_f="14521">All comers ARDS</offsets></td><td align="center"><offsets xml_i="24501" xml_f="24515" txt_i="14522" txt_f="14536">Pneumonia ARDS</offsets></td><td align="center"><offsets xml_i="24539" xml_f="24554" txt_i="14537" txt_f="14552">All comers ARDS</offsets></td><td align="center"><offsets xml_i="24578" xml_f="24593" txt_i="14553" txt_f="14568">All comers ARDS</offsets></td><td align="center"><offsets xml_i="24617" xml_f="24642" txt_i="14569" txt_f="14591">ARDS network (age &lt;70)</offsets></td><td align="center"><offsets xml_i="24666" xml_f="24684" txt_i="14592" txt_f="14607">Pa02/FiO2 &lt; 200</offsets></td></tr><tr><td align="left"><offsets xml_i="24715" xml_f="24727" txt_i="14608" txt_f="14620">Intervention</offsets></td><td align="center"><offsets xml_i="24751" xml_f="24791" txt_i="14621" txt_f="14661">Ventilation-controlled or high frequency</offsets></td><td align="center"><offsets xml_i="24815" xml_f="24847" txt_i="14662" txt_f="14694">Tidal volume 12 ml/kg or 6 ml/kg</offsets></td><td align="center"><offsets xml_i="24871" xml_f="24887" txt_i="14695" txt_f="14711">Supine vs. prone</offsets></td><td align="center"><offsets xml_i="24911" xml_f="24935" txt_i="14712" txt_f="14736">Placebo vs. ketoconazole</offsets></td><td align="center"><offsets xml_i="24959" xml_f="24991" txt_i="14737" txt_f="14769">Tidal volume 12 ml/kg or 6 ml/kg</offsets></td><td align="center"><offsets xml_i="25015" xml_f="25057" txt_i="14770" txt_f="14812">Cisatracurium 0/4 twitches or 2/4 twitches</offsets></td></tr><tr><td align="left"><offsets xml_i="25088" xml_f="25101" txt_i="14813" txt_f="14826"># of subjects</offsets></td><td align="center"><offsets xml_i="25125" xml_f="25128" txt_i="14827" txt_f="14830">147</offsets></td><td align="center"><offsets xml_i="25152" xml_f="25155" txt_i="14831" txt_f="14834">320</offsets></td><td align="center"><offsets xml_i="25179" xml_f="25182" txt_i="14835" txt_f="14838">304</offsets></td><td align="center"><offsets xml_i="25206" xml_f="25209" txt_i="14839" txt_f="14842">234</offsets></td><td align="center"><offsets xml_i="25233" xml_f="25236" txt_i="14843" txt_f="14846">729</offsets></td><td align="center"><offsets xml_i="25260" xml_f="25263" txt_i="14847" txt_f="14850">102</offsets></td></tr><tr><td align="left"><offsets xml_i="25294" xml_f="25308" txt_i="14851" txt_f="14865">Mean age (yrs)</offsets></td><td align="center"><offsets xml_i="25332" xml_f="25334" txt_i="14866" txt_f="14868">49</offsets></td><td align="center"><offsets xml_i="25358" xml_f="25360" txt_i="14869" txt_f="14871">51</offsets></td><td align="center"><offsets xml_i="25384" xml_f="25386" txt_i="14872" txt_f="14874">58</offsets></td><td align="center"><offsets xml_i="25410" xml_f="25412" txt_i="14875" txt_f="14877">53</offsets></td><td align="center"><offsets xml_i="25436" xml_f="25438" txt_i="14878" txt_f="14880">46</offsets></td><td align="center"><offsets xml_i="25462" xml_f="25464" txt_i="14881" txt_f="14883">56</offsets></td></tr><tr><td align="left"><offsets xml_i="25495" xml_f="25514" txt_i="14884" txt_f="14903">Severity of illness</offsets></td><td align="center"><offsets xml_i="25538" xml_f="25542" txt_i="14904" txt_f="14908">22**</offsets></td><td align="center"><offsets xml_i="25566" xml_f="25571" txt_i="14909" txt_f="14914">84***</offsets></td><td align="center"><offsets xml_i="25595" xml_f="25598" txt_i="14915" txt_f="14918">40*</offsets></td><td align="center"><offsets xml_i="25622" xml_f="25627" txt_i="14919" txt_f="14924">81***</offsets></td><td align="center"><offsets xml_i="25651" xml_f="25656" txt_i="14925" txt_f="14930">73***</offsets></td><td align="center"><offsets xml_i="25680" xml_f="25683" txt_i="14931" txt_f="14934">41*</offsets></td></tr><tr><td align="left"><offsets xml_i="25714" xml_f="25723" txt_i="14935" txt_f="14944">Pa02/FiO2</offsets></td><td align="center"><offsets xml_i="25747" xml_f="25750" txt_i="14945" txt_f="14948">113</offsets></td><td align="center"><offsets xml_i="25774" xml_f="25777" txt_i="14949" txt_f="14952">133</offsets></td><td align="center"><offsets xml_i="25801" xml_f="25804" txt_i="14953" txt_f="14956">127</offsets></td><td align="center"><offsets xml_i="25828" xml_f="25831" txt_i="14957" txt_f="14960">145</offsets></td><td></td><td align="center"><offsets xml_i="25864" xml_f="25867" txt_i="14962" txt_f="14965">130</offsets></td></tr><tr><td align="left"><offsets xml_i="25898" xml_f="25906" txt_i="14966" txt_f="14974">ICU days</offsets></td><td></td><td></td><td></td><td></td><td align="center"><offsets xml_i="25966" xml_f="25968" txt_i="14979" txt_f="14981">19</offsets></td><td></td></tr><tr><td align="left"><offsets xml_i="26008" xml_f="26026" txt_i="14983" txt_f="15001">Days on ventilator</offsets></td><td align="center"><offsets xml_i="26050" xml_f="26052" txt_i="15002" txt_f="15004">21</offsets></td><td></td><td></td><td></td><td align="center"><offsets xml_i="26103" xml_f="26105" txt_i="15008" txt_f="15010">10</offsets></td><td></td></tr><tr><td align="left"><offsets xml_i="26145" xml_f="26166" txt_i="15012" txt_f="15033">In-hospital mortality</offsets></td><td></td><td></td><td></td><td align="center"><offsets xml_i="26217" xml_f="26220" txt_i="15037" txt_f="15040">35%</offsets></td><td></td><td align="center"><offsets xml_i="26253" xml_f="26256" txt_i="15042" txt_f="15045">45%</offsets></td></tr><tr><td align="left"><offsets xml_i="26287" xml_f="26323" txt_i="15046" txt_f="15082">% with unassisted breathing at 1 mth</offsets></td><td></td><td align="center"><offsets xml_i="26356" xml_f="26359" txt_i="15084" txt_f="15087">57%</offsets></td><td></td><td align="center"><offsets xml_i="26392" xml_f="26395" txt_i="15089" txt_f="15092">59%</offsets></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="26444" xml_f="26460" txt_i="15095" txt_f="15111">10 day mortality</offsets></td><td></td><td></td><td align="center"><offsets xml_i="26502" xml_f="26510" txt_i="15114" txt_f="15122">25%, 21%</offsets></td><td></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="26568" xml_f="26584" txt_i="15126" txt_f="15142">30 day mortality</offsets></td><td align="center"><offsets xml_i="26608" xml_f="26616" txt_i="15143" txt_f="15151">52%, 37%</offsets></td><td></td><td></td><td></td><td align="center"><offsets xml_i="26667" xml_f="26670" txt_i="15155" txt_f="15158">25%</offsets></td><td></td></tr><tr><td align="left"><offsets xml_i="26710" xml_f="26725" txt_i="15160" txt_f="15175">6 mth mortality</offsets></td><td align="center"><offsets xml_i="26749" xml_f="26757" txt_i="15176" txt_f="15184">59%, 47%</offsets></td><td align="center"><offsets xml_i="26781" xml_f="26784" txt_i="15185" txt_f="15188">36%</offsets></td><td align="center"><offsets xml_i="26808" xml_f="26816" txt_i="15189" txt_f="15197">59%, 63%</offsets></td><td></td><td align="center"><offsets xml_i="26849" xml_f="26852" txt_i="15199" txt_f="15202">30%</offsets></td><td></td></tr><tr><td align="left"><offsets xml_i="26892" xml_f="26929" txt_i="15204" txt_f="15241">Ventilator free days in first 28 days</offsets></td><td></td><td></td><td></td><td align="center"><offsets xml_i="26980" xml_f="26982" txt_i="15245" txt_f="15247">10</offsets></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="27031" xml_f="27043" txt_i="15250" txt_f="15262">reintubation</offsets></td><td></td><td></td><td></td><td></td><td align="center"><offsets xml_i="27103" xml_f="27107" txt_i="15267" txt_f="15271">7.5%</offsets></td><td></td></tr></tbody></table></table-wrap><table-wrap position="float" id="T6"><label><offsets xml_i="27199" xml_f="27206" txt_i="15273" txt_f="15280">Table 6</offsets></label><caption><p><offsets xml_i="27226" xml_f="27283" txt_i="15280" txt_f="15337">Cohort studies of patients with ARDS published after 1999</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold><offsets xml_i="27368" xml_f="27374" txt_i="15338" txt_f="15344">Author</offsets></bold></td><td align="center"><bold><offsets xml_i="27411" xml_f="27421" txt_i="15345" txt_f="15355">Estenssoro</offsets></bold><sup><offsets xml_i="27433" xml_f="27435" txt_i="15355" txt_f="15357">46</offsets></sup></td><td align="center"><bold><offsets xml_i="27471" xml_f="27475" txt_i="15358" txt_f="15362">Luhr</offsets></bold><sup><offsets xml_i="27487" xml_f="27489" txt_i="15362" txt_f="15364">47</offsets></sup></td><td align="center"><bold><offsets xml_i="27525" xml_f="27533" txt_i="15365" txt_f="15373">Davidson</offsets></bold><sup><offsets xml_i="27545" xml_f="27547" txt_i="15373" txt_f="15375">48</offsets></sup></td><td align="center"><bold><offsets xml_i="27583" xml_f="27591" txt_i="15376" txt_f="15384">Arroliga</offsets></bold><sup><offsets xml_i="27603" xml_f="27605" txt_i="15384" txt_f="15386">49</offsets></sup></td><td align="center"><bold><offsets xml_i="27641" xml_f="27649" txt_i="15387" txt_f="15395">Reynolds</offsets></bold><sup><offsets xml_i="27661" xml_f="27663" txt_i="15395" txt_f="15397">50</offsets></sup></td><td align="center"><bold><offsets xml_i="27699" xml_f="27704" txt_i="15398" txt_f="15403">Angus</offsets></bold><sup><offsets xml_i="27716" xml_f="27718" txt_i="15403" txt_f="15405">13</offsets></sup></td><td align="center"><bold><offsets xml_i="27754" xml_f="27761" txt_i="15406" txt_f="15413">Fialkow</offsets></bold><sup><offsets xml_i="27773" xml_f="27775" txt_i="15413" txt_f="15415">51</offsets></sup></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="27827" xml_f="27837" txt_i="15416" txt_f="15426">Study type</offsets></td><td align="center"><offsets xml_i="27861" xml_f="27872" txt_i="15427" txt_f="15438">prospective</offsets></td><td align="center"><offsets xml_i="27896" xml_f="27907" txt_i="15439" txt_f="15450">prospective</offsets></td><td align="center"><offsets xml_i="27931" xml_f="27942" txt_i="15451" txt_f="15462">prospective</offsets></td><td align="center"><offsets xml_i="27966" xml_f="27979" txt_i="15463" txt_f="15476">retrospective</offsets></td><td align="center"><offsets xml_i="28003" xml_f="28016" txt_i="15477" txt_f="15490">retrospective</offsets></td><td align="center"><offsets xml_i="28040" xml_f="28051" txt_i="15491" txt_f="15502">prospective</offsets></td><td align="center"><offsets xml_i="28075" xml_f="28088" txt_i="15503" txt_f="15516">retrospective</offsets></td></tr><tr><td align="left"><offsets xml_i="28119" xml_f="28132" txt_i="15517" txt_f="15530"># of subjects</offsets></td><td align="center"><offsets xml_i="28156" xml_f="28159" txt_i="15531" txt_f="15534">235</offsets></td><td align="center"><offsets xml_i="28183" xml_f="28186" txt_i="15535" txt_f="15538">221</offsets></td><td align="center"><offsets xml_i="28210" xml_f="28213" txt_i="15539" txt_f="15542">127</offsets></td><td align="center"><offsets xml_i="28237" xml_f="28239" txt_i="15543" txt_f="15545">66</offsets></td><td align="center"><offsets xml_i="28263" xml_f="28266" txt_i="15546" txt_f="15549">720</offsets></td><td align="center"><offsets xml_i="28290" xml_f="28293" txt_i="15550" txt_f="15553">200</offsets></td><td align="center"><offsets xml_i="28317" xml_f="28319" txt_i="15554" txt_f="15556">30</offsets></td></tr><tr><td align="left"><offsets xml_i="28350" xml_f="28364" txt_i="15557" txt_f="15571">Mean age (yrs)</offsets></td><td align="center"><offsets xml_i="28388" xml_f="28390" txt_i="15572" txt_f="15574">55</offsets></td><td align="center"><offsets xml_i="28414" xml_f="28416" txt_i="15575" txt_f="15577">61</offsets></td><td align="center"><offsets xml_i="28440" xml_f="28442" txt_i="15578" txt_f="15580">39</offsets></td><td align="center"><offsets xml_i="28466" xml_f="28468" txt_i="15581" txt_f="15583">60</offsets></td><td></td><td align="center"><offsets xml_i="28501" xml_f="28503" txt_i="15585" txt_f="15587">49</offsets></td><td align="center"><offsets xml_i="28527" xml_f="28529" txt_i="15588" txt_f="15590">51</offsets></td></tr><tr><td align="left"><offsets xml_i="28560" xml_f="28579" txt_i="15591" txt_f="15610">Severity of illness</offsets></td><td align="center"><offsets xml_i="28603" xml_f="28607" txt_i="15611" txt_f="15615">21**</offsets></td><td align="center"><offsets xml_i="28631" xml_f="28635" txt_i="15616" txt_f="15620">19**</offsets></td><td align="center"><offsets xml_i="28659" xml_f="28664" txt_i="15621" txt_f="15626">73***</offsets></td><td align="center"><offsets xml_i="28688" xml_f="28692" txt_i="15627" txt_f="15631">23**</offsets></td><td></td><td align="center"><offsets xml_i="28725" xml_f="28729" txt_i="15633" txt_f="15637">17**</offsets></td><td align="center"><offsets xml_i="28753" xml_f="28757" txt_i="15638" txt_f="15642">18**</offsets></td></tr><tr><td align="left"><offsets xml_i="28788" xml_f="28797" txt_i="15643" txt_f="15652">Pa02/FiO2</offsets></td><td align="center"><offsets xml_i="28821" xml_f="28824" txt_i="15653" txt_f="15656">141</offsets></td><td align="center"><offsets xml_i="28848" xml_f="28851" txt_i="15657" txt_f="15660">131</offsets></td><td></td><td align="center"><offsets xml_i="28884" xml_f="28887" txt_i="15662" txt_f="15665">111</offsets></td><td></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="28945" xml_f="28961" txt_i="15669" txt_f="15685">ICU days (range)</offsets></td><td></td><td></td><td></td><td align="center"><offsets xml_i="29012" xml_f="29014" txt_i="15689" txt_f="15691">12</offsets></td><td></td><td align="center"><offsets xml_i="29047" xml_f="29056" txt_i="15693" txt_f="15702">16 (0–93)</offsets></td><td align="center"><offsets xml_i="29080" xml_f="29082" txt_i="15703" txt_f="15705">21</offsets></td></tr><tr><td align="left"><offsets xml_i="29113" xml_f="29128" txt_i="15706" txt_f="15721">Ventilator days</offsets></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="29222" xml_f="29243" txt_i="15729" txt_f="15750">Hospital days (range)</offsets></td><td></td><td></td><td align="center"><offsets xml_i="29285" xml_f="29294" txt_i="15753" txt_f="15762">28(1–150)</offsets></td><td></td><td></td><td align="center"><offsets xml_i="29336" xml_f="29346" txt_i="15765" txt_f="15775">26 (0–117)</offsets></td><td align="center"><offsets xml_i="29370" xml_f="29372" txt_i="15776" txt_f="15778">44</offsets></td></tr><tr><td align="left"><offsets xml_i="29403" xml_f="29418" txt_i="15779" txt_f="15794">3 day mortality</offsets></td><td align="center"><offsets xml_i="29442" xml_f="29445" txt_i="15795" txt_f="15798">34%</offsets></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="29530" xml_f="29543" txt_i="15805" txt_f="15818">ICU mortality</offsets></td><td></td><td></td><td></td><td align="center"><offsets xml_i="29594" xml_f="29597" txt_i="15822" txt_f="15825">47%</offsets></td><td></td><td></td><td align="center"><offsets xml_i="29639" xml_f="29642" txt_i="15828" txt_f="15831">47%</offsets></td></tr><tr><td align="left"><offsets xml_i="29673" xml_f="29694" txt_i="15832" txt_f="15853">In-hospital mortality</offsets></td><td align="center"><offsets xml_i="29718" xml_f="29721" txt_i="15854" txt_f="15857">58%</offsets></td><td></td><td align="center"><offsets xml_i="29754" xml_f="29757" txt_i="15859" txt_f="15862">43%</offsets></td><td></td><td align="center"><offsets xml_i="29790" xml_f="29793" txt_i="15864" txt_f="15867">36%</offsets></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="29842" xml_f="29858" txt_i="15870" txt_f="15886">30 day mortality</offsets></td><td></td><td align="center"><offsets xml_i="29891" xml_f="29894" txt_i="15888" txt_f="15891">41%</offsets></td><td></td><td align="center"><offsets xml_i="29927" xml_f="29930" txt_i="15893" txt_f="15896">49%</offsets></td><td></td><td align="center"><offsets xml_i="29963" xml_f="29968" txt_i="15898" txt_f="15903">30.5%</offsets></td><td></td></tr><tr><td align="left"><offsets xml_i="30008" xml_f="30023" txt_i="15905" txt_f="15920">6 mth mortality</offsets></td><td></td><td></td><td></td><td></td><td></td><td align="center"><offsets xml_i="30092" xml_f="30097" txt_i="15926" txt_f="15931">44.3%</offsets></td><td></td></tr><tr><td align="left"><offsets xml_i="30137" xml_f="30151" txt_i="15933" txt_f="15947">1 yr mortality</offsets></td><td></td><td></td><td align="center"><offsets xml_i="30193" xml_f="30196" txt_i="15950" txt_f="15953">47%</offsets></td><td></td><td></td><td align="center"><offsets xml_i="30238" xml_f="30241" txt_i="15956" txt_f="15959">44%</offsets></td><td></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="30296" xml_f="30328" txt_i="15961" txt_f="15993">* SAPS; **Apache 2; *** Apache 3</offsets></p></table-wrap-foot></table-wrap><table-wrap position="float" id="T7"><label><offsets xml_i="30407" xml_f="30414" txt_i="15994" txt_f="16001">Table 7</offsets></label><caption><p><offsets xml_i="30434" xml_f="30514" txt_i="16001" txt_f="16081">ICU studies of mechanically ventilated patients receiving neuromuscular blockers</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center"><bold><offsets xml_i="30610" xml_f="30616" txt_i="16083" txt_f="16089">Newman</offsets></bold><sup><offsets xml_i="30628" xml_f="30630" txt_i="16089" txt_f="16091">52</offsets></sup></td><td align="center"><bold><offsets xml_i="30666" xml_f="30671" txt_i="16092" txt_f="16097">Rudis</offsets></bold><sup><offsets xml_i="30683" xml_f="30685" txt_i="16097" txt_f="16099">53</offsets></sup></td><td align="center"><bold><offsets xml_i="30721" xml_f="30727" txt_i="16100" txt_f="16106">Kupfer</offsets></bold><sup><offsets xml_i="30739" xml_f="30741" txt_i="16106" txt_f="16108">54</offsets></sup></td><td align="center"><bold><offsets xml_i="30777" xml_f="30785" txt_i="16109" txt_f="16117">Douglass</offsets></bold><sup><offsets xml_i="30797" xml_f="30799" txt_i="16117" txt_f="16119">55</offsets></sup></td><td align="center"><bold><offsets xml_i="30835" xml_f="30843" txt_i="16120" txt_f="16128">Prielipp</offsets></bold><sup><offsets xml_i="30855" xml_f="30856" txt_i="16128" txt_f="16129">4</offsets></sup></td><td align="center"><bold><offsets xml_i="30892" xml_f="30899" txt_i="16130" txt_f="16137">Segredo</offsets></bold><sup><offsets xml_i="30911" xml_f="30913" txt_i="16137" txt_f="16139">56</offsets></sup></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="30965" xml_f="30975" txt_i="16140" txt_f="16150">Study type</offsets></td><td align="left"><offsets xml_i="30997" xml_f="31008" txt_i="16151" txt_f="16162">Prospective</offsets></td><td align="left"><offsets xml_i="31030" xml_f="31041" txt_i="16163" txt_f="16174">Prospective</offsets></td><td align="left"><offsets xml_i="31063" xml_f="31074" txt_i="16175" txt_f="16186">Prospective</offsets></td><td align="left"><offsets xml_i="31096" xml_f="31109" txt_i="16187" txt_f="16200">Retrospective</offsets></td><td align="left"><offsets xml_i="31131" xml_f="31142" txt_i="16201" txt_f="16212">Prospective</offsets></td><td align="left"><offsets xml_i="31164" xml_f="31175" txt_i="16213" txt_f="16224">Prospective</offsets></td></tr><tr><td align="left"><offsets xml_i="31206" xml_f="31216" txt_i="16225" txt_f="16235">Randomized</offsets></td><td align="left"><offsets xml_i="31238" xml_f="31241" txt_i="16236" txt_f="16239">Yes</offsets></td><td align="left"><offsets xml_i="31263" xml_f="31266" txt_i="16240" txt_f="16243">Yes</offsets></td><td align="left"><offsets xml_i="31288" xml_f="31290" txt_i="16244" txt_f="16246">No</offsets></td><td align="left"><offsets xml_i="31312" xml_f="31314" txt_i="16247" txt_f="16249">No</offsets></td><td align="left"><offsets xml_i="31336" xml_f="31339" txt_i="16250" txt_f="16253">Yes</offsets></td><td align="left"><offsets xml_i="31361" xml_f="31363" txt_i="16254" txt_f="16256">No</offsets></td></tr><tr><td align="left"><offsets xml_i="31394" xml_f="31402" txt_i="16257" txt_f="16265">Patients</offsets></td><td align="center"><offsets xml_i="31426" xml_f="31429" txt_i="16266" txt_f="16269">ICU</offsets></td><td align="center"><offsets xml_i="31453" xml_f="31456" txt_i="16270" txt_f="16273">ICU</offsets></td><td align="center"><offsets xml_i="31480" xml_f="31494" txt_i="16274" txt_f="16285">VEC &gt; 6 hrs</offsets></td><td align="center"><offsets xml_i="31518" xml_f="31524" txt_i="16286" txt_f="16292">Asthma</offsets></td><td align="center"><offsets xml_i="31548" xml_f="31551" txt_i="16293" txt_f="16296">ICU</offsets></td><td align="center"><offsets xml_i="31575" xml_f="31588" txt_i="16297" txt_f="16307">VEC&gt;24 hrs</offsets></td></tr><tr><td align="left"><offsets xml_i="31619" xml_f="31632" txt_i="16308" txt_f="16321"># of subjects</offsets></td><td align="left"><offsets xml_i="31654" xml_f="31656" txt_i="16322" txt_f="16324">61</offsets></td><td align="left"><offsets xml_i="31678" xml_f="31680" txt_i="16325" txt_f="16327">77</offsets></td><td align="left"><offsets xml_i="31702" xml_f="31704" txt_i="16328" txt_f="16330">10</offsets></td><td align="left"><offsets xml_i="31726" xml_f="31728" txt_i="16331" txt_f="16333">25</offsets></td><td align="left"><offsets xml_i="31750" xml_f="31752" txt_i="16334" txt_f="16336">54</offsets></td><td align="left"><offsets xml_i="31774" xml_f="31776" txt_i="16337" txt_f="16339">16</offsets></td></tr><tr><td align="left"><offsets xml_i="31807" xml_f="31820" txt_i="16340" txt_f="16353">Mean age(yrs)</offsets></td><td align="left"><offsets xml_i="31842" xml_f="31844" txt_i="16354" txt_f="16356">51</offsets></td><td align="left"><offsets xml_i="31866" xml_f="31868" txt_i="16357" txt_f="16359">54</offsets></td><td align="left"><offsets xml_i="31890" xml_f="31892" txt_i="16360" txt_f="16362">34</offsets></td><td align="left"><offsets xml_i="31914" xml_f="31916" txt_i="16363" txt_f="16365">39</offsets></td><td align="left"><offsets xml_i="31938" xml_f="31940" txt_i="16366" txt_f="16368">49</offsets></td><td></td></tr><tr><td align="left"><offsets xml_i="31980" xml_f="31992" txt_i="16370" txt_f="16382">Apache score</offsets></td><td align="left"><offsets xml_i="32014" xml_f="32016" txt_i="16383" txt_f="16385">18</offsets></td><td align="left"><offsets xml_i="32038" xml_f="32040" txt_i="16386" txt_f="16388">73</offsets></td><td></td><td></td><td align="left"><offsets xml_i="32080" xml_f="32082" txt_i="16391" txt_f="16393">27</offsets></td><td></td></tr><tr><td align="left"><offsets xml_i="32122" xml_f="32143" txt_i="16395" txt_f="16416">Neuromuscular blocker</offsets></td><td align="left"><offsets xml_i="32165" xml_f="32195" txt_i="16417" txt_f="16447">CISATRA (n = 40) ATRA (n = 21)</offsets></td><td align="left"><offsets xml_i="32217" xml_f="32280" txt_i="16448" txt_f="16511">VEC (n = 35 standard Assessment; N= 42 nerve stim) 65 survivors</offsets></td><td align="left"><offsets xml_i="32302" xml_f="32305" txt_i="16512" txt_f="16515">VEC</offsets></td><td align="left"><offsets xml_i="32327" xml_f="32343" txt_i="16516" txt_f="16532">VEC 22 of 25 pts</offsets></td><td align="left"><offsets xml_i="32365" xml_f="32395" txt_i="16533" txt_f="16563">CISTATRA (n = 28) VEC (n = 30)</offsets></td><td align="left"><offsets xml_i="32417" xml_f="32420" txt_i="16564" txt_f="16567">VEC</offsets></td></tr><tr><td align="left"><offsets xml_i="32451" xml_f="32462" txt_i="16568" txt_f="16579">Dose (mean)</offsets></td><td align="left"><offsets xml_i="32484" xml_f="32525" txt_i="16580" txt_f="16621">CISATRA 3.1 ug/kg/min ATRA 10.4 ug/kg/min</offsets></td><td align="left"><offsets xml_i="32547" xml_f="32611" txt_i="16622" txt_f="16686">VEC load 0.08 mg/kg infusion 0.08 mg/kg/hr dosing individualized</offsets></td><td></td><td align="left"><offsets xml_i="32642" xml_f="32659" txt_i="16688" txt_f="16705">492 mg (SD692 mg)</offsets></td><td align="left"><offsets xml_i="32681" xml_f="32734" txt_i="16706" txt_f="16759">CISTATRA 2.6 mg/kg/hr VEC 0.9 mg/kg/hr twitch monitor</offsets></td><td></td></tr><tr><td align="left"><offsets xml_i="32774" xml_f="32794" txt_i="16761" txt_f="16781">Duration of infusion</offsets></td><td align="left"><offsets xml_i="32816" xml_f="32822" txt_i="16782" txt_f="16788">47 hrs</offsets></td><td align="left"><offsets xml_i="32844" xml_f="32914" txt_i="16789" txt_f="16859">Standard assessment- 55.1 +/- 34.3 hrs Nerve stimulation 43.2 +/- 31.8</offsets></td><td></td><td align="left"><offsets xml_i="32945" xml_f="32953" txt_i="16861" txt_f="16869">6.6 days</offsets></td><td align="left"><offsets xml_i="32975" xml_f="33011" txt_i="16870" txt_f="16906">CISTATRA 80 +/- 7 h VEC 66 +/- 12 h.</offsets></td><td></td></tr><tr><td align="left"><offsets xml_i="33051" xml_f="33070" txt_i="16908" txt_f="16927">Recovery from block</offsets></td><td align="left"><offsets xml_i="33092" xml_f="33121" txt_i="16928" txt_f="16957">1 hour 70% TOF for both drugs</offsets></td><td align="left"><offsets xml_i="33143" xml_f="33243" txt_i="16958" txt_f="17058">50% of control pts recovery was 3.5 hrs (95% CI 2–8) vs. 1.7 hrs (95% CI 1–2) in nerve stim patients</offsets></td><td align="left"><offsets xml_i="33265" xml_f="33333" txt_i="17059" txt_f="17127">7/10 pts with weakness, 3/10 muscle wasting, 2/10 difficulty weaning</offsets></td><td></td><td align="left"><offsets xml_i="33364" xml_f="33439" txt_i="17129" txt_f="17204">70% TOF ratio CISTATRA 68 +/- 13 min VEC 387 +/- 163 min, longer (P = 0.02)</offsets></td><td align="left"><offsets xml_i="33461" xml_f="33510" txt_i="17205" txt_f="17254">7 of 16 pts had prolonged block (l6 hrs – 7 days)</offsets></td></tr><tr><td align="left"><offsets xml_i="33541" xml_f="33564" txt_i="17255" txt_f="17278">Neuro- muscular Outcome</offsets></td><td align="left"><offsets xml_i="33586" xml_f="33676" txt_i="17279" txt_f="17369">No patient showed evidence of weakness following discontinuation of either CISATRA or ATRA</offsets></td><td align="left"><offsets xml_i="33698" xml_f="33815" txt_i="17370" txt_f="17487">Median time for 50% of control pts to breathe spontaneously was 4.8 hrs (95% CI 3–9) compared with 2 hrs (95% CI 2–5)</offsets><break></break><offsets xml_i="33830" xml_f="33935" txt_i="17487" txt_f="17586">11 of 35 control pts had prolonged block (&gt;4 hr) 5/42 perip nerve stim pts had long block (p &lt; .05)</offsets><break></break><offsets xml_i="33950" xml_f="34004" txt_i="17586" txt_f="17640">3 survivors needed physical therapy for 35 to 137 days</offsets></td><td align="left"><offsets xml_i="34026" xml_f="34069" txt_i="17641" txt_f="17684">Pts with polyneuropathy 1352 mg in 7.2 days</offsets><break></break><offsets xml_i="34084" xml_f="34134" txt_i="17684" txt_f="17734">Without polyneuropathy 528 mg for 3.8 days (p0.04)</offsets></td><td align="left"><offsets xml_i="34156" xml_f="34254" txt_i="17735" txt_f="17830">9/25 had weakness Patients with myopathy had significantly higher total dose of VEC (p &lt; 0.001)</offsets></td><td align="left"><offsets xml_i="34276" xml_f="34343" txt_i="17831" txt_f="17898">Prolonged recovery CISTATRA: 2 patients VEC : 13 patients P = 0.002</offsets><break></break><offsets xml_i="34358" xml_f="34392" txt_i="17898" txt_f="17932">1 VEC patient significant myopathy</offsets></td><td></td></tr><tr><td></td><td align="center"><bold><offsets xml_i="34449" xml_f="34456" txt_i="17935" txt_f="17942">deLemos</offsets></bold><sup><offsets xml_i="34468" xml_f="34470" txt_i="17942" txt_f="17944">57</offsets></sup></td><td align="center"><bold><offsets xml_i="34506" xml_f="34518" txt_i="17945" txt_f="17957">Khuenl-Brady</offsets></bold><sup><offsets xml_i="34530" xml_f="34532" txt_i="17957" txt_f="17959">58</offsets></sup></td><td align="center"><bold><offsets xml_i="34568" xml_f="34578" txt_i="17960" txt_f="17970">Leatherman</offsets></bold><sup><offsets xml_i="34590" xml_f="34592" txt_i="17970" txt_f="17972">59</offsets></sup></td><td align="center"><bold><offsets xml_i="34628" xml_f="34635" txt_i="17973" txt_f="17980">Coakley</offsets></bold><sup><offsets xml_i="34647" xml_f="34649" txt_i="17980" txt_f="17982">60</offsets></sup></td><td align="center"><bold><offsets xml_i="34685" xml_f="34691" txt_i="17983" txt_f="17989">Murray</offsets></bold><sup><offsets xml_i="34703" xml_f="34705" txt_i="17989" txt_f="17991">61</offsets></sup></td><td align="center"><bold><offsets xml_i="34741" xml_f="34748" txt_i="17992" txt_f="17999">Coakley</offsets></bold><sup><offsets xml_i="34760" xml_f="34762" txt_i="17999" txt_f="18001">62</offsets></sup></td></tr><tr><td align="left"><offsets xml_i="34799" xml_f="34809" txt_i="18002" txt_f="18012">Study Type</offsets></td><td align="left"><offsets xml_i="34831" xml_f="34842" txt_i="18013" txt_f="18024">Prospective</offsets></td><td align="left"><offsets xml_i="34864" xml_f="34875" txt_i="18025" txt_f="18036">Prospective</offsets></td><td align="left"><offsets xml_i="34897" xml_f="34910" txt_i="18037" txt_f="18050">Retrospective</offsets></td><td align="left"><offsets xml_i="34932" xml_f="34943" txt_i="18051" txt_f="18062">Prospective</offsets></td><td align="left"><offsets xml_i="34965" xml_f="34976" txt_i="18063" txt_f="18074">Prospective</offsets></td><td align="left"><offsets xml_i="34998" xml_f="35009" txt_i="18075" txt_f="18086">Prospective</offsets></td></tr><tr><td align="left"><offsets xml_i="35040" xml_f="35050" txt_i="18087" txt_f="18097">Randomized</offsets></td><td align="center"><offsets xml_i="35074" xml_f="35076" txt_i="18098" txt_f="18100">No</offsets></td><td align="center"><offsets xml_i="35100" xml_f="35102" txt_i="18101" txt_f="18103">No</offsets></td><td align="center"><offsets xml_i="35126" xml_f="35128" txt_i="18104" txt_f="18106">No</offsets></td><td align="center"><offsets xml_i="35152" xml_f="35154" txt_i="18107" txt_f="18109">No</offsets></td><td align="center"><offsets xml_i="35178" xml_f="35181" txt_i="18110" txt_f="18113">Yes</offsets></td><td align="center"><offsets xml_i="35205" xml_f="35207" txt_i="18114" txt_f="18116">No</offsets></td></tr><tr><td align="left"><offsets xml_i="35238" xml_f="35246" txt_i="18117" txt_f="18125">Patients</offsets></td><td align="center"><offsets xml_i="35270" xml_f="35273" txt_i="18126" txt_f="18129">ICU</offsets></td><td align="center"><offsets xml_i="35297" xml_f="35314" txt_i="18130" txt_f="18144">Block &gt; 2 days</offsets></td><td align="center"><offsets xml_i="35338" xml_f="35344" txt_i="18145" txt_f="18151">Asthma</offsets></td><td align="center"><offsets xml_i="35368" xml_f="35382" txt_i="18152" txt_f="18163">ICU &gt;7 days</offsets></td><td align="center"><offsets xml_i="35406" xml_f="35409" txt_i="18164" txt_f="18167">ICU</offsets></td><td align="center"><offsets xml_i="35433" xml_f="35447" txt_i="18168" txt_f="18179">ICU &gt;7 days</offsets></td></tr><tr><td align="left"><offsets xml_i="35478" xml_f="35491" txt_i="18180" txt_f="18193"># of subjects</offsets></td><td align="center"><offsets xml_i="35515" xml_f="35517" txt_i="18194" txt_f="18196">30</offsets></td><td align="center"><offsets xml_i="35541" xml_f="35543" txt_i="18197" txt_f="18199">60</offsets></td><td align="center"><offsets xml_i="35567" xml_f="35570" txt_i="18200" txt_f="18203">107</offsets></td><td align="center"><offsets xml_i="35594" xml_f="35596" txt_i="18204" txt_f="18206">44</offsets></td><td align="center"><offsets xml_i="35620" xml_f="35622" txt_i="18207" txt_f="18209">40</offsets></td><td align="center"><offsets xml_i="35646" xml_f="35648" txt_i="18210" txt_f="18212">23</offsets></td></tr><tr><td align="left"><offsets xml_i="35679" xml_f="35693" txt_i="18213" txt_f="18227">Mean age (yrs)</offsets></td><td align="center"><offsets xml_i="35717" xml_f="35719" txt_i="18228" txt_f="18230">42</offsets></td><td align="center"><offsets xml_i="35743" xml_f="35745" txt_i="18231" txt_f="18233">36</offsets></td><td></td><td align="center"><offsets xml_i="35778" xml_f="35780" txt_i="18235" txt_f="18237">60</offsets></td><td align="center"><offsets xml_i="35804" xml_f="35806" txt_i="18238" txt_f="18240">52</offsets></td><td align="center"><offsets xml_i="35830" xml_f="35832" txt_i="18241" txt_f="18243">55</offsets></td></tr><tr><td align="left"><offsets xml_i="35863" xml_f="35869" txt_i="18244" txt_f="18250">Apache</offsets></td><td align="center"><offsets xml_i="35893" xml_f="35895" txt_i="18251" txt_f="18253">26</offsets></td><td></td><td></td><td align="center"><offsets xml_i="35937" xml_f="35939" txt_i="18256" txt_f="18258">19</offsets></td><td align="center"><offsets xml_i="35963" xml_f="35965" txt_i="18259" txt_f="18261">27</offsets></td><td align="center"><offsets xml_i="35989" xml_f="35993" txt_i="18262" txt_f="18266">15.9</offsets></td></tr><tr><td align="left"><offsets xml_i="36024" xml_f="36042" txt_i="18267" txt_f="18285">Neuromusc. blocker</offsets></td><td align="left"><offsets xml_i="36064" xml_f="36085" txt_i="18286" txt_f="18307">PANC with TOF titrate</offsets></td><td align="left"><offsets xml_i="36107" xml_f="36134" txt_i="18308" txt_f="18335">PANC (n = 30) PIPE (n = 30)</offsets></td><td align="left"><offsets xml_i="36156" xml_f="36171" txt_i="18336" txt_f="18351">ATRA, PANC, VEC</offsets></td><td></td><td align="left"><offsets xml_i="36202" xml_f="36211" txt_i="18353" txt_f="18362">DOX, PANC</offsets></td><td align="left"><offsets xml_i="36233" xml_f="36250" txt_i="18363" txt_f="18380">15 of 23 received</offsets></td></tr><tr><td align="left"><offsets xml_i="36281" xml_f="36292" txt_i="18381" txt_f="18392">Dose (mean)</offsets></td><td align="left"><offsets xml_i="36314" xml_f="36398" txt_i="18393" txt_f="18477">Intermittent group (n = 14) 0.02 mg/kg/hr) Continuous Infusion (n = 16) .04 mg/kg/hr</offsets></td><td align="left"><offsets xml_i="36420" xml_f="36436" txt_i="18478" txt_f="18494">3 mg/h with both</offsets></td><td></td><td></td><td align="left"><offsets xml_i="36476" xml_f="36510" txt_i="18497" txt_f="18531">DOX (0.04 mg/kg) PANC (0.07 mg/kg)</offsets></td><td></td></tr><tr><td align="left"><offsets xml_i="36550" xml_f="36570" txt_i="18533" txt_f="18553">Duration Of infusion</offsets></td><td align="left"><offsets xml_i="36592" xml_f="36598" txt_i="18554" txt_f="18560">6 days</offsets></td><td align="left"><offsets xml_i="36620" xml_f="36631" txt_i="18561" txt_f="18569">&gt; 48 hrs</offsets></td><td></td><td align="left"><offsets xml_i="36662" xml_f="36673" txt_i="18571" txt_f="18579">&gt; 7 days</offsets></td><td align="left"><offsets xml_i="36695" xml_f="36703" txt_i="18580" txt_f="18588">2.5 days</offsets></td><td></td></tr><tr><td align="left"><offsets xml_i="36743" xml_f="36762" txt_i="18590" txt_f="18609">Recovery from block</offsets></td><td align="left"><offsets xml_i="36784" xml_f="36924" txt_i="18610" txt_f="18750">Median time to recover from paralysis was 3.5 hrs (1.82–5.18) in infusion group vs. 6.3 hrs (3.40–9.19) in intermittent bolus group (p =.10)</offsets></td><td></td><td align="left"><offsets xml_i="36955" xml_f="37046" txt_i="18752" txt_f="18840">Corticosteroids associated with more muscle weakness 20 of 69 versus 0 of 38 (p &lt; 0.001)</offsets></td><td></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="37104" xml_f="37127" txt_i="18844" txt_f="18867">Neuro- muscular Outcome</offsets></td><td align="left"><offsets xml_i="37149" xml_f="37229" txt_i="18868" txt_f="18948">5 in the infusion group and 1 intermittent had persistent severe muscle weakness</offsets><break></break><offsets xml_i="37244" xml_f="37296" txt_i="18948" txt_f="18997">3 from each group had prolonged recovery &gt;12 hrs.</offsets></td><td align="left"><offsets xml_i="37318" xml_f="37358" txt_i="18998" txt_f="19038">None of the patients had muscle weakness</offsets></td><td align="left"><offsets xml_i="37380" xml_f="37466" txt_i="19039" txt_f="19122">20 weak patients were paralysed longer 3.4 +/- 2.4 versus 0.6 +/- 0.7 d (p &lt; 0.001)</offsets><break></break><offsets xml_i="37481" xml_f="37519" txt_i="19122" txt_f="19157">18 of 20 weak pts paralysed &gt; 24 h.</offsets></td><td align="left"><offsets xml_i="37541" xml_f="37577" txt_i="19158" txt_f="19190">19 had motor &amp; sensory findingss</offsets><break></break><offsets xml_i="37592" xml_f="37713" txt_i="19190" txt_f="19307">no relationship between neurophys. abnormality &amp; APACHE II score, organ failure, sepsis, muscle relaxant, or steroids</offsets><break></break><offsets xml_i="37728" xml_f="37741" txt_i="19307" txt_f="19320">Mortality 23%</offsets></td><td align="left"><offsets xml_i="37763" xml_f="37847" txt_i="19321" txt_f="19402">DOX shorter recovery time after &gt;2 days of administration. (279.8 vs. 138.8 mins)</offsets><break></break><offsets xml_i="37862" xml_f="37903" txt_i="19402" txt_f="19443">no cases of prolonged neuromuscular block</offsets></td><td align="left"><offsets xml_i="37925" xml_f="37983" txt_i="19444" txt_f="19502">10/23 had EMG, 9 of 10 had axonopathy, 8 were sensorimotor</offsets><break></break><offsets xml_i="37998" xml_f="38011" txt_i="19502" txt_f="19515">Mortality 21%</offsets></td></tr></tbody></table></table-wrap><p><offsets xml_i="38053" xml_f="38375" txt_i="19516" txt_f="19838">Assuming society would be willing to pay $35,000 for an additional quality adjusted life (i.e., ceiling ratio), even if a drug (that cost $267 more) did reduce AQMS from 25% to 21% and decrease intubation time by 6 hours, the net monetary benefit would only equal $137. By running repeated iterations of the model, Figure </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="38405" xml_f="38406" txt_i="19838" txt_f="19839">2</offsets></xref><offsets xml_i="38413" xml_f="38745" txt_i="19839" txt_f="20171"> has a scatter plot of the joint distribution of the mean incremental costs (mean decrease US $96, SD $5,134) and mean incremental QALYs (mean increase of 0.12, SD 0.0159) gained for bootstrap samples. For the base case, the net monetary benefit of reducing both AQMS and ventilation time would be positive for only 51% of patients.</offsets></p><fig position="float" id="F2"><label><offsets xml_i="38786" xml_f="38794" txt_i="20172" txt_f="20180">Figure 2</offsets></label><caption><p><bold><offsets xml_i="38820" xml_f="38852" txt_i="20180" txt_f="20212">The results of computer modeling</offsets></bold><offsets xml_i="38859" xml_f="39016" txt_i="20212" txt_f="20369">. The x- axis has the mean incremental QALYs and the y-axis has the mean incremental costs for the 10,000 Monte-Carlo simulations, each represented by a dot.</offsets></p></caption><graphic xlink:href="1472-6947-6-15-2"></graphic></fig></sec><sec><title><offsets xml_i="39103" xml_f="39123" txt_i="20371" txt_f="20391">Sensitivity analysis</offsets></title><p><offsets xml_i="39134" xml_f="39407" txt_i="20392" txt_f="20665">The net monetary benefit was positive for 50% of simulations with a ceiling ratio of $1,000 versus 51% if the ceiling ratio was increased to $100,000. The lack of sensitivity was caused by the mean changes in QALY and cost to be small relative to their standard deviations.</offsets></p><p><offsets xml_i="39414" xml_f="39764" txt_i="20666" txt_f="21016">The variables that had the largest influence on the results, from most to least important, were probability from ICU intubated to death, probability from ICU intubated to extubated, and probability from ICU extubated to ward. The better the patients do overall, the larger the net monetary benefit of a drug that reduces AQMS and/or intubation times.</offsets></p></sec></sec><sec><title><offsets xml_i="39792" xml_f="39802" txt_i="21019" txt_f="21029">Discussion</offsets></title><p><offsets xml_i="39813" xml_f="40436" txt_i="21030" txt_f="21653">To properly allocate research money, computerized economic modeling should be first used to determine whether a pharmacoeconomic study can be expected to have a significant finding and thus be undertaken. ARDS patients receiving a neuromuscular blocker have a high mortality, and unpredictable outcome, which results in large variability in costs per case. If a patient dies, there is no benefit to any drug or intervention that reduces ventilation time or AQMS incidence. Consequently, a prospective, randomized pharmacoeconomic study of neuromuscular blockers in the ICU to assess AQMS or intubation times is impractical.</offsets></p><p><offsets xml_i="40443" xml_f="40966" txt_i="21654" txt_f="22177">Published studies comparing neuromuscular blockers in the ICU for ARDS are limited by the heterogeneity of study methods and outcomes (e.g., each study defined myopathy/weakness differently). We found that the best way to increase net monetary benefit would be for the drug to affect the key variable – the chance of a patient dying. The benefit in spending extra money on such a drug is more likely to be important in a subset of critically ill patients identified as having prolonged intubation and a low chance of death.</offsets></p><sec><title><offsets xml_i="40982" xml_f="41017" txt_i="22178" txt_f="22213">Neuromuscular blockers and recovery</offsets></title><p><offsets xml_i="41028" xml_f="41699" txt_i="22214" txt_f="22885">The optimal balance between sedation and paralysis in ARDS patients is unclear. Since the probability of having a positive net monetary benefit is only for 51% of patients, practitioners choosing neuromuscular blockers need to consider risk factors for a patient developing AQMS such as female gender, the number of days with dysfunction of two or more organs, duration of mechanical ventilation, and administration of corticosteroids. It may be that the recognition of the problem of AQMS and consequent avoidance of or decrease in dosing of neuromuscular blockers, particularly when corticosteroids are given concurrently, in the ICU has reduced the incidence of AQMS [</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="41731" xml_f="41733" txt_i="22885" txt_f="22887">19</offsets></xref><offsets xml_i="41740" xml_f="41742" txt_i="22887" txt_f="22889">].</offsets></p></sec><sec><title><offsets xml_i="41764" xml_f="41803" txt_i="22891" txt_f="22930">Assessing validity of computer modeling</offsets></title><p><offsets xml_i="41814" xml_f="42179" txt_i="22931" txt_f="23296">The challenge is to design a useful model. Had we chosen to evaluate just the portion of care that occurs in the ICU, there would be less clinical uncertainty, because we would neglect what happened to the patient after ICU discharge. On the other hand, by including a six-month time frame, there is increasing uncertainty related to the complex course of the ARDS.</offsets></p><p><offsets xml_i="42186" xml_f="42695" txt_i="23297" txt_f="23806">We tested the robustness of our modeling by comparing what our computer simulation predicted with published studies documenting the natural clinical progression of ARDS patients. For example, our model predicted that 28% of patients (base case being a 55 year- with pneumonia ARDS receiving neuromuscular blockade for 3.5 days) would be discharged home after 6 months, and that 18% would receive care in a long-term care facility. Both endpoints are consistent with a previous study of discharge disposition [</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="42727" xml_f="42729" txt_i="23806" txt_f="23808">20</offsets></xref><offsets xml_i="42736" xml_f="42856" txt_i="23808" txt_f="23928">]. Our model also predicts that patients would have 15 ventilator free days, which matches well with published studies [</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="42888" xml_f="42890" txt_i="23928" txt_f="23930">21</offsets></xref><offsets xml_i="42897" xml_f="42941" txt_i="23930" txt_f="23974">]. Thus, the scattergram obtained in Figure </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="42971" xml_f="42972" txt_i="23974" txt_f="23975">2</offsets></xref><offsets xml_i="42979" xml_f="43112" txt_i="23975" txt_f="24108"> reflects the uncertainties about how the probabilities will change if a new drug is used to reduce delays in neuromuscular recovery.</offsets></p></sec><sec><title><offsets xml_i="43134" xml_f="43148" txt_i="24110" txt_f="24124">Costing issues</offsets></title><p><offsets xml_i="43159" xml_f="43350" txt_i="24125" txt_f="24316">Each facility may be able to negotiate individual contracts for neuromuscular blockers so the cost differences we estimated based on average wholesale price may not apply to a particular ICU.</offsets></p><p><offsets xml_i="43357" xml_f="43620" txt_i="24317" txt_f="24580">Prolonged recovery from neuromuscular blockade may add costs due to additional sedative drugs, mechanical ventilation, and physician and nurse, ICU time. Importantly, the majority of the costs of treating patients with ARDS are spent on those who eventually die [</offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="43652" xml_f="43654" txt_i="24580" txt_f="24582">22</offsets></xref><offsets xml_i="43661" xml_f="43909" txt_i="24582" txt_f="24830">]. A detailed costing study of 193 critically ill adults found that factors such as severity of illness, gender, age, mechanical ventilation, emergency admission, and mortality were only able to explain 34% of the variation in average daily costs [</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="43941" xml_f="43943" txt_i="24830" txt_f="24832">23</offsets></xref><offsets xml_i="43950" xml_f="43952" txt_i="24832" txt_f="24834">].</offsets></p><p><offsets xml_i="43959" xml_f="44851" txt_i="24835" txt_f="25727">It may be that a good way to reduce time on mechanical ventilation is to have a full time intensivist rounding in the ICU 10–12 hours a day repeatedly evaluating the patient for extubation. However, in many ICUs this may not be available. A six-hour reduction in time on the ventilator may not be applicable in such settings. Although from society's perspective six-hours of ventilator time is important and measurable, from the hospital's perspective most of the cost of ICU care is a fixed cost. Even if a patient spends three hours less in the ICU, institutional costs may not be affected significantly because of the high overhead costs of hospital care. Different ICUs will have a different proportion of variable costs. In fact, nursing labor productivity is most sensitive to the number of admissions to the ICU each year and the method of compensating nurses (e.g., salary or hourly).</offsets></p></sec></sec><sec><title><offsets xml_i="44879" xml_f="44889" txt_i="25730" txt_f="25740">Conclusion</offsets></title><p><offsets xml_i="44900" xml_f="45652" txt_i="25741" txt_f="26493">The multifactorial etiology of AQMS, the highly variable clinical course of patients with ARDS as well as the disease's high mortality rate, makes the determination of whether selection of certain neuromuscular blockers decreases the incidence of AQMS or reduces intubation time difficult to answer. Our simulation computer model predicted the mean cost for ARDS patients receiving standard care for 6 months to be $62,238, with an overall 6-month mortality of 39%. Although it would be important to determine if a particular neuromuscular blocker diminishes the incidence of AQMS, a prospective, randomized pharmacoeconomic study of neuromuscular blockers in the ICU is impractical because of the highly variable clinical course of patients with ARDS.</offsets></p></sec><sec><title><offsets xml_i="45674" xml_f="45693" txt_i="26495" txt_f="26514">Competing interests</offsets></title><p><offsets xml_i="45704" xml_f="45936" txt_i="26515" txt_f="26747">This study was funded in part by Abbott Laboratories, 100 Abbott Park Road Abbott Park, Illinois. Abbott Laboratories did not participate in the collection, analysis, or interpretation of the results contained within the manuscript.</offsets></p></sec><sec><title><offsets xml_i="45958" xml_f="45980" txt_i="26749" txt_f="26771">Authors' contributions</offsets></title><p><offsets xml_i="45991" xml_f="46301" txt_i="26772" txt_f="27082">AM conceived the study, outlined the economic model, and wrote the manuscript. JLC led the literature review, and provided expert clinical guidance as to the clinical message. FD participated in the design of the study and performed the statistical analysis. All authors read and approved the final manuscript.</offsets></p></sec><sec><title><offsets xml_i="46323" xml_f="46346" txt_i="27084" txt_f="27107">Pre-publication history</offsets></title><p><offsets xml_i="46357" xml_f="46421" txt_i="27108" txt_f="27172">The pre-publication history for this paper can be accessed here:</offsets></p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1472-6947/6/15/prepub"></ext-link></p></sec></body><back><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bernard</surname><given-names>GR</given-names></name><name><surname>Artigas</surname><given-names>A</given-names></name><name><surname>Brigham</surname><given-names>KL</given-names></name><name><surname>Carlet</surname><given-names>J</given-names></name><name><surname>Falke</surname><given-names>K</given-names></name><name><surname>Hudson</surname><given-names>L</given-names></name><name><surname>Lamy</surname><given-names>M</given-names></name><name><surname>LeGall</surname><given-names>JR</given-names></name><name><surname>Morris</surname><given-names>A</given-names></name><name><surname>Spragg</surname><given-names>R</given-names></name></person-group><article-title>The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination</article-title><source>Am J Respir Crit Care Med</source><year>1994</year><volume>149</volume><fpage>818</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">7509706</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Jonghe</surname><given-names>B</given-names></name><name><surname>Sharshar</surname><given-names>T</given-names></name><name><surname>Lefaucheur</surname><given-names>JP</given-names></name><name><surname>Authier</surname><given-names>FJ</given-names></name><name><surname>Durand-Zaleski</surname><given-names>I</given-names></name><name><surname>Boussarsar</surname><given-names>M</given-names></name><name><surname>Cerf</surname><given-names>C</given-names></name><name><surname>Renaud</surname><given-names>E</given-names></name><name><surname>Mesrati</surname><given-names>F</given-names></name><name><surname>Carlet</surname><given-names>J</given-names></name><name><surname>Raphael</surname><given-names>JC</given-names></name><name><surname>Outin</surname><given-names>H</given-names></name><name><surname>Bastuji-Garin</surname><given-names>S</given-names></name><collab>Groupe de Reflexion et d'Etude des Neuromyopathies en Reanimation</collab></person-group><article-title>Paresis acquired in the intensive care unit: a prospective multicenter study</article-title><source>JAMA</source><year>2002</year><volume>288</volume><fpage>2859</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">12472328</pub-id><pub-id pub-id-type="doi">10.1001/jama.288.22.2859</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>MJ</given-names></name><name><surname>Cowen</surname><given-names>J</given-names></name><name><surname>DeBlock</surname><given-names>H</given-names></name><name><surname>Erstad</surname><given-names>B</given-names></name><name><surname>Gray</surname><given-names>AW</given-names><suffix>Jr</suffix></name><name><surname>Tescher</surname><given-names>AN</given-names></name><name><surname>McGee</surname><given-names>WT</given-names></name><name><surname>Prielipp</surname><given-names>RC</given-names></name><name><surname>Susla</surname><given-names>G</given-names></name><name><surname>Jacobi</surname><given-names>J</given-names></name><name><surname>Nasraway</surname><given-names>SA</given-names><suffix>Jr</suffix></name><name><surname>Lumb</surname><given-names>PD</given-names></name><collab>Task Force of the American College of Critical Care Medicine (ACCM) of the Society of Critical Care Medicine (SCCM), American Society of Health-System Pharmacists, American College of Chest Physicians</collab></person-group><article-title>Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient</article-title><source>Crit Care Med</source><year>2002</year><volume>30</volume><fpage>142</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">11902255</pub-id><pub-id pub-id-type="doi">10.1097/00003246-200201000-00021</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prielipp</surname><given-names>RC</given-names></name><name><surname>Coursin</surname><given-names>DB</given-names></name><name><surname>Scuderi</surname><given-names>PE</given-names></name><name><surname>Bowton</surname><given-names>DL</given-names></name><name><surname>Ford</surname><given-names>SR</given-names></name><name><surname>Cardenas</surname><given-names>VJ</given-names><suffix>Jr</suffix></name><name><surname>Vender</surname><given-names>J</given-names></name><name><surname>Howard</surname><given-names>D</given-names></name><name><surname>Casale</surname><given-names>EJ</given-names></name><name><surname>Murray</surname><given-names>MJ</given-names></name></person-group><article-title>Comparison of the infusion requirements and recovery profiles of vecuronium and cisatracurium 51W89 in intensive care unit patients</article-title><source>Anesth Analg</source><year>1995</year><volume>81</volume><fpage>3</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">7598277</pub-id><pub-id pub-id-type="doi">10.1097/00000539-199507000-00002</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>L</given-names></name><name><surname>Gold</surname><given-names>M</given-names></name><name><surname>Siegel</surname><given-names>J</given-names></name><name><surname>Daniels</surname><given-names>N</given-names></name><name><surname>Winstein</surname><given-names>M</given-names></name></person-group><article-title>The role of cost-effectiveness analysis in health and medicine: Panel on cost-effectiveness in health and medicine</article-title><source>JAMA</source><year>1996</year><volume>276</volume><fpage>1172</fpage><lpage>1177</lpage><pub-id pub-id-type="pmid">8827972</pub-id><pub-id pub-id-type="doi">10.1001/jama.276.14.1172</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Escolano</surname><given-names>S</given-names></name><name><surname>Golmard</surname><given-names>JL</given-names></name><name><surname>Korinek</surname><given-names>AM</given-names></name><name><surname>Mallet</surname><given-names>A</given-names></name></person-group><article-title>A multi-state model for evolution of intensive care unit patients: prediction of nosocomial infections and deaths</article-title><source>Stat Med</source><year>2000</year><volume>19</volume><fpage>3465</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">11122508</pub-id><pub-id pub-id-type="doi">10.1002/1097-0258(20001230)19:24&lt;3465::AID-SIM658&gt;3.0.CO;2-6</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rangel-Frausto</surname><given-names>MS</given-names></name><name><surname>Pittet</surname><given-names>D</given-names></name><name><surname>Hwang</surname><given-names>T</given-names></name><name><surname>Woolson</surname><given-names>RF</given-names></name><name><surname>Wenzel</surname><given-names>RP</given-names></name></person-group><article-title>The dynamics of disease progression in sepsis: Markov modeling describing the natural history and the likely impact of effective antisepsis agents</article-title><source>Clin Infect Dis</source><year>1998</year><volume>27</volume><fpage>185</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">9675475</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O'Brien</surname><given-names>BJ</given-names></name><name><surname>Briggs</surname><given-names>AH</given-names></name></person-group><article-title>Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods</article-title><source>Stat Methods Med Res</source><year>2002</year><volume>11</volume><fpage>455</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">12516984</pub-id><pub-id pub-id-type="doi">10.1191/0962280202sm304ra</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stinett</surname><given-names>AA</given-names></name><name><surname>Mullahy</surname><given-names>J</given-names></name></person-group><article-title>Net health benefits: A new framework for the analysis of uncertainty in cost-effectiveness analysis</article-title><source>Med Decis Making</source><year>1998</year><volume>18</volume><fpage>S68</fpage><lpage>S80</lpage><pub-id pub-id-type="pmid">9566468</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lothgren</surname><given-names>M</given-names></name><name><surname>Zethraeus</surname><given-names>N</given-names></name></person-group><article-title>Definition, interpretation and calculation of cost-effectiveness acceptability curves</article-title><source>Health Econ</source><year>2000</year><volume>9</volume><fpage>623</fpage><lpage>630</lpage><pub-id pub-id-type="pmid">11103928</pub-id><pub-id pub-id-type="doi">10.1002/1099-1050(200010)9:7&lt;623::AID-HEC539&gt;3.0.CO;2-V</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Noseworthy</surname><given-names>TW</given-names></name><name><surname>Konopad</surname><given-names>E</given-names></name><name><surname>Shustack</surname><given-names>A</given-names></name><name><surname>Johnston</surname><given-names>R</given-names></name><name><surname>Grace</surname><given-names>M</given-names></name></person-group><article-title>Cost accounting of adult intensive care: methods and human and capital inputs</article-title><source>Crit Care Med</source><year>1996</year><volume>24</volume><fpage>1168</fpage><lpage>1172</lpage><pub-id pub-id-type="pmid">8674330</pub-id><pub-id pub-id-type="doi">10.1097/00003246-199607000-00017</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heyland</surname><given-names>DK</given-names></name><name><surname>Guyatt</surname><given-names>G</given-names></name><name><surname>Cook</surname><given-names>DJ</given-names></name><name><surname>Meade</surname><given-names>M</given-names></name><name><surname>Juniper</surname><given-names>E</given-names></name><name><surname>Cronin</surname><given-names>L</given-names></name><name><surname>Gafni</surname><given-names>A</given-names></name></person-group><article-title>Frequency and methodologic rigor of quality-of-life assessments in the critical care literature</article-title><source>Crit Care Med</source><year>1998</year><volume>26</volume><fpage>591</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9504591</pub-id><pub-id pub-id-type="doi">10.1097/00003246-199803000-00037</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Angus</surname><given-names>DC</given-names></name><name><surname>Musthafa</surname><given-names>AA</given-names></name><name><surname>Clermont</surname><given-names>G</given-names></name><name><surname>Griffin</surname><given-names>MF</given-names></name><name><surname>Linde-Zwirble</surname><given-names>WT</given-names></name><name><surname>Dremsizov</surname><given-names>TT</given-names></name><name><surname>Pinsky</surname><given-names>MR</given-names></name></person-group><article-title>Quality-adjusted survival in the first year after the acute respiratory distress syndrome</article-title><source>Am J Respir Crit Care Med</source><year>2001</year><volume>163</volume><fpage>1389</fpage><lpage>1394</lpage><pub-id pub-id-type="pmid">11371406</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kerridge</surname><given-names>RK</given-names></name><name><surname>Glasziou</surname><given-names>PP</given-names></name><name><surname>Hillman</surname><given-names>KM</given-names></name></person-group><article-title>The use of 'quality-adjusted life years' (QALYs) to evaluate treatment in intensive care</article-title><source>Anaesth Intensive Care</source><year>1995</year><volume>23</volume><fpage>322</fpage><lpage>331</lpage><pub-id pub-id-type="pmid">7573919</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosser</surname><given-names>R</given-names></name><name><surname>Kind</surname><given-names>P</given-names></name></person-group><article-title>A scale of valuations of states of illness: is there a social consensus?</article-title><source>Int J Epidemiol</source><year>1978</year><volume>7</volume><fpage>347</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">744673</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><collab>The EuroQol Group</collab></person-group><article-title>EuroQol-a new facility for the measurement of health-related quality of life</article-title><source>Health Policy</source><year>1990</year><volume>16</volume><fpage>199</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">10109801</pub-id><pub-id pub-id-type="doi">10.1016/0168-8510(90)90421-9</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Doubilet</surname><given-names>P</given-names></name><name><surname>Begg</surname><given-names>C</given-names></name><name><surname>Weinstein</surname><given-names>M</given-names></name><name><surname>Braun</surname><given-names>P</given-names></name><name><surname>McNeil</surname><given-names>B</given-names></name></person-group><article-title>Probabilitic senstivity analysis using Monte-Carlo simulation</article-title><source>Med Dec Making</source><year>1985</year><volume>5</volume><fpage>157</fpage><lpage>77</lpage></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><collab>No authors listed</collab></person-group><article-title>Understanding costs and cost-effectiveness in critical care: report from the second American Thoracic Society workshop on outcomes research</article-title><source>Am J Respir Crit Care Med</source><year>2002</year><volume>165</volume><fpage>540</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">11850349</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frankel</surname><given-names>H</given-names></name><name><surname>Jeng</surname><given-names>J</given-names></name><name><surname>Tilly</surname><given-names>E</given-names></name><name><surname>St Andre</surname><given-names>A</given-names></name><name><surname>Champion</surname><given-names>H</given-names></name></person-group><article-title>The impact of implementation of neuromuscular blockade monitoring standards in a surgical intensive care unit</article-title><source>Am Surg</source><year>1996</year><volume>62</volume><fpage>503</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">8651538</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spicher</surname><given-names>JE</given-names></name><name><surname>White</surname><given-names>DP</given-names></name></person-group><article-title>Outcome and function following prolonged mechanical ventilation</article-title><source>Arch Intern Med</source><year>1987</year><volume>147</volume><fpage>421</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">3827415</pub-id><pub-id pub-id-type="doi">10.1001/archinte.147.3.421</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schoenfeld</surname><given-names>DA</given-names></name><name><surname>Bernard</surname><given-names>GR</given-names></name></person-group><article-title>Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome</article-title><source>Crit Care Med</source><year>2002</year><volume>30</volume><fpage>1772</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12163791</pub-id><pub-id pub-id-type="doi">10.1097/00003246-200208000-00016</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shorr</surname><given-names>AF</given-names></name></person-group><article-title>An update on cost-effectiveness analysis in critical care</article-title><source>Curr Opin Crit Care</source><year>2002</year><volume>8</volume><fpage>337</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">12386495</pub-id><pub-id pub-id-type="doi">10.1097/00075198-200208000-00011</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jacobs</surname><given-names>P</given-names></name><name><surname>Edbrooke</surname><given-names>D</given-names></name><name><surname>Hibbert</surname><given-names>C</given-names></name><name><surname>Fassbender</surname><given-names>K</given-names></name><name><surname>Corcoran</surname><given-names>M</given-names></name></person-group><article-title>Descriptive patient data as an explanation for the variation in average daily costs in intensive care</article-title><source>Anaesthesia</source><year>2001</year><volume>56</volume><fpage>643</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">11437764</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2044.2001.02052.x</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Edbrooke</surname><given-names>DL</given-names></name><name><surname>Ridley</surname><given-names>SA</given-names></name><name><surname>Hibbert</surname><given-names>CL</given-names></name><name><surname>Corcoran</surname><given-names>M</given-names></name></person-group><article-title>Variations in expenditure between adult general intensive care units in the UK</article-title><source>Anaesthesia</source><year>2001</year><volume>56</volume><fpage>208</fpage><lpage>216</lpage><pub-id pub-id-type="pmid">11251425</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2044.2001.01716.x</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Graf</surname><given-names>J</given-names></name><name><surname>Graf</surname><given-names>C</given-names></name><name><surname>Janssens</surname><given-names>U</given-names></name></person-group><article-title>Analysis of resource use and cost-generating factors in a German medical intensive care unit employing the Therapeutic Intervention Scoring System (TISS-28)</article-title><source>Intensive Care Med</source><year>2002</year><volume>28</volume><fpage>324</fpage><lpage>331</lpage><pub-id pub-id-type="pmid">11904663</pub-id><pub-id pub-id-type="doi">10.1007/s00134-001-1201-6</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Flaatten</surname><given-names>H</given-names></name><name><surname>Reider</surname><given-names>K</given-names></name></person-group><article-title>Cost of intensive care in a Norwegian University hospital 1997–1999</article-title><source>Critical Care</source><year>2002</year><volume>7</volume><fpage>72</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">12617743</pub-id><pub-id pub-id-type="doi">10.1186/cc1865</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Manns</surname><given-names>BJ</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Doig</surname><given-names>CJ</given-names></name><name><surname>Johnson</surname><given-names>D</given-names></name><name><surname>Donaldson</surname><given-names>C</given-names></name></person-group><article-title>An economic evaluation of activated protein C treatment for severe sepsis</article-title><source>N Engl J Med</source><year>2002</year><volume>347</volume><fpage>993</fpage><lpage>1000</lpage><pub-id pub-id-type="pmid">12324556</pub-id><pub-id pub-id-type="doi">10.1056/NEJMsa020969</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heyland</surname><given-names>DK</given-names></name><name><surname>Konopad</surname><given-names>E</given-names></name><name><surname>Noseworthy</surname><given-names>TW</given-names></name><name><surname>Johnston</surname><given-names>R</given-names></name><name><surname>Gafni</surname><given-names>A</given-names></name></person-group><article-title>Is it "worthwhile" to continue treating patients with a prolonged stay (&gt;14 days) in the ICU? An economic evaluation</article-title><source>Chest</source><year>1998</year><volume>114</volume><fpage>192</fpage><lpage>198</lpage><pub-id pub-id-type="pmid">9674469</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chaix</surname><given-names>C</given-names></name><name><surname>Durand Zaleski</surname><given-names>I</given-names></name><name><surname>Alberti</surname><given-names>C</given-names></name><name><surname>Brun-Buisson</surname><given-names>C</given-names></name></person-group><article-title>A model to compute the medical cost of patients in intensive care</article-title><source>Pharmacoeconomics</source><year>1999</year><volume>15</volume><fpage>573</fpage><lpage>582</lpage><pub-id pub-id-type="pmid">10538330</pub-id><pub-id pub-id-type="doi">10.2165/00019053-199915060-00005</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taheri</surname><given-names>PA</given-names></name><name><surname>Butz</surname><given-names>DA</given-names></name><name><surname>Greenfield</surname><given-names>LJ</given-names></name></person-group><article-title>Length of stay has minimal impact on the cost of hospital admission</article-title><source>J Am Coll Surg</source><year>2000</year><volume>191</volume><fpage>123</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">10945354</pub-id><pub-id pub-id-type="doi">10.1016/S1072-7515(00)00352-5</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dasgupta</surname><given-names>A</given-names></name><name><surname>Rice</surname><given-names>R</given-names></name><name><surname>Mascha</surname><given-names>E</given-names></name><name><surname>Litaker</surname><given-names>D</given-names></name><name><surname>Stoller</surname><given-names>JK</given-names></name></person-group><article-title>Four-year experience with a unit for long-term ventilation (respiratory special care unit) at the Cleveland Clinic Foundation</article-title><source>Chest</source><year>1999</year><volume>116</volume><fpage>447</fpage><lpage>455</lpage><pub-id pub-id-type="pmid">10453875</pub-id><pub-id pub-id-type="doi">10.1378/chest.116.2.447</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsevat</surname><given-names>J</given-names></name><name><surname>Cook</surname><given-names>EF</given-names></name><name><surname>Green</surname><given-names>ML</given-names></name><name><surname>Matchar</surname><given-names>DB</given-names></name><name><surname>Dawson</surname><given-names>NV</given-names></name><name><surname>Broste</surname><given-names>SK</given-names></name><name><surname>Wu</surname><given-names>AW</given-names></name><name><surname>Phillips</surname><given-names>RS</given-names></name><name><surname>Oye</surname><given-names>RK</given-names></name><name><surname>Goldman</surname><given-names>L</given-names></name></person-group><article-title>Health values of the seriously ill. SUPPORT Investigators</article-title><source>Ann Intern Med</source><year>1995</year><volume>122</volume><fpage>514</fpage><lpage>520</lpage><pub-id pub-id-type="pmid">7872587</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>CL</given-names></name><name><surname>Liu</surname><given-names>TL</given-names></name><name><surname>Wu</surname><given-names>LJ</given-names></name><name><surname>Chung</surname><given-names>UL</given-names></name><name><surname>Lee</surname><given-names>LC</given-names></name></person-group><article-title>Cost and care quality between licensed nursing homes under different types of ownership</article-title><source>J Nurs Res</source><year>2002</year><volume>10</volume><fpage>151</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">12119600</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sznajder</surname><given-names>M</given-names></name><name><surname>Aegerter</surname><given-names>P</given-names></name><name><surname>Launois</surname><given-names>R</given-names></name><name><surname>Merliere</surname><given-names>Y</given-names></name><name><surname>CubRea</surname><given-names></given-names></name></person-group><article-title>A cost-effectiveness analysis of stays in intensive care units</article-title><source>Intensive Care Med</source><year>2001</year><volume>27</volume><fpage>146</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">11280626</pub-id><pub-id pub-id-type="doi">10.1007/s001340000760</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nichol</surname><given-names>MB</given-names></name><name><surname>Sengupta</surname><given-names>N</given-names></name><name><surname>Globe</surname><given-names>DR</given-names></name></person-group><article-title>Evaluating quality-adjusted life years: estimation of the health utility index (HUI2) from the SF-36</article-title><source>Med Decis Making</source><year>2001</year><volume>21</volume><fpage>105</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">11310943</pub-id><pub-id pub-id-type="doi">10.1177/02729890122062352</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>TA</given-names></name><name><surname>Caldwell</surname><given-names>ES</given-names></name><name><surname>Curtis</surname><given-names>JR</given-names></name><name><surname>Hudson</surname><given-names>LD</given-names></name><name><surname>Steinberg</surname><given-names>KP</given-names></name></person-group><article-title>Reduced quality of life in survivors of acute respiratory distress syndrome compared with critically ill control patients</article-title><source>JAMA</source><year>1999</year><volume>281</volume><fpage>354</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">9929089</pub-id><pub-id pub-id-type="doi">10.1001/jama.281.4.354</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>AB</given-names></name><name><surname>Ferguson</surname><given-names>ND</given-names></name><name><surname>Hanly</surname><given-names>PJ</given-names></name><name><surname>Meade</surname><given-names>MO</given-names></name><name><surname>Kachura</surname><given-names>JR</given-names></name><name><surname>Granton</surname><given-names>JT</given-names></name><name><surname>Slutsky</surname><given-names>AS</given-names></name><name><surname>Stewart</surname><given-names>TE</given-names></name></person-group><article-title>Long-term follow-up of survivors of acute lung injury: lack of effect of a ventilation strategy to prevent barotrauma</article-title><source>Crit Care Med</source><year>1999</year><volume>27</volume><fpage>2616</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">10628599</pub-id><pub-id pub-id-type="doi">10.1097/00003246-199912000-00002</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hamel</surname><given-names>MB</given-names></name><name><surname>Phillips</surname><given-names>RS</given-names></name><name><surname>Davis</surname><given-names>RB</given-names></name><name><surname>Teno</surname><given-names>J</given-names></name><name><surname>Connors</surname><given-names>AF</given-names></name><name><surname>Desbiens</surname><given-names>N</given-names></name><name><surname>Lynn</surname><given-names>J</given-names></name><name><surname>Dawson</surname><given-names>NV</given-names></name><name><surname>Fulkerson</surname><given-names>W</given-names></name><name><surname>Tsevat</surname><given-names>J</given-names></name></person-group><article-title>Outcomes and cost-effectiveness of ventilator support and aggressive care for patients with acute respiratory failure due to pneumonia or acute respiratory distress syndrome</article-title><source>Am J Med</source><year>2000</year><volume>109</volume><fpage>614</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">11099680</pub-id><pub-id pub-id-type="doi">10.1016/S0002-9343(00)00591-X</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McHugh</surname><given-names>LG</given-names></name><name><surname>Milberg</surname><given-names>JA</given-names></name><name><surname>Whitcomb</surname><given-names>ME</given-names></name><name><surname>Schoene</surname><given-names>RB</given-names></name><name><surname>Maunder</surname><given-names>RJ</given-names></name><name><surname>Hudson</surname><given-names>LD</given-names></name></person-group><article-title>Recovery of function in survivors of the acute respiratory distress syndrome</article-title><source>Am J Respir Crit Care Med</source><year>1994</year><volume>150</volume><fpage>90</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">8025779</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Derdak</surname><given-names>S</given-names></name><name><surname>Mehta</surname><given-names>S</given-names></name><name><surname>Stewart</surname><given-names>TE</given-names></name><name><surname>Smith</surname><given-names>T</given-names></name><name><surname>Rogers</surname><given-names>M</given-names></name><name><surname>Buchman</surname><given-names>TG</given-names></name><name><surname>Carlin</surname><given-names>B</given-names></name><name><surname>Lowson</surname><given-names>S</given-names></name><name><surname>Granton</surname><given-names>J</given-names></name><collab>Multicenter Oscillatory Ventilation For Acute Respiratory Distress Syndrome Trial (MOAT) Study Investigators</collab></person-group><article-title>High-frequency oscillatory ventilation for acute respiratory distress syndrome in adults: a randomized, controlled trial</article-title><source>Am J Respir Crit Care Med</source><year>2002</year><volume>166</volume><fpage>801</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">12231488</pub-id><pub-id pub-id-type="doi">10.1164/rccm.2108052</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eisner</surname><given-names>MD</given-names></name><name><surname>Thompson</surname><given-names>T</given-names></name><name><surname>Hudson</surname><given-names>LD</given-names></name><name><surname>Luce</surname><given-names>JM</given-names></name><name><surname>Hayden</surname><given-names>D</given-names></name><name><surname>Schoenfeld</surname><given-names>D</given-names></name><name><surname>Matthay</surname><given-names>MA</given-names></name><collab>Acute Respiratory Distress Syndrome Network</collab></person-group><article-title>Efficacy of low tidal volume ventilation in patients with different clinical risk factors for acute lung injury and the acute respiratory distress syndrome</article-title><source>Am J Respir Crit Care Med</source><year>2001</year><volume>164</volume><fpage>231</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">11463593</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gattinoni</surname><given-names>L</given-names></name><name><surname>Tognoni</surname><given-names>G</given-names></name><name><surname>Pesenti</surname><given-names>A</given-names></name><name><surname>Taccone</surname><given-names>P</given-names></name><name><surname>Mascheroni</surname><given-names>D</given-names></name><name><surname>Labarta</surname><given-names>V</given-names></name><name><surname>Malacrida</surname><given-names>R</given-names></name><name><surname>Di Giulio</surname><given-names>P</given-names></name><name><surname>Fumagalli</surname><given-names>R</given-names></name><name><surname>Pelosi</surname><given-names>P</given-names></name><name><surname>Brazzi</surname><given-names>L</given-names></name><name><surname>Latini</surname><given-names>R</given-names></name><collab>Prone-Supine Study Group</collab></person-group><article-title>Effect of prone positioning on the survival of patients with acute respiratory failure</article-title><source>N Engl J Med</source><year>2001</year><volume>345</volume><fpage>568</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">11529210</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa010043</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><collab>No authors listed</collab></person-group><article-title>Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. The ARDS Network</article-title><source>JAMA</source><year>2000</year><volume>283</volume><fpage>1995</fpage><lpage>2002</lpage><pub-id pub-id-type="pmid">10789668</pub-id><pub-id pub-id-type="doi">10.1001/jama.283.15.1995</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ely</surname><given-names>EW</given-names></name><name><surname>Wheeler</surname><given-names>AP</given-names></name><name><surname>Thompson</surname><given-names>BT</given-names></name><name><surname>Ancukiewicz</surname><given-names>M</given-names></name><name><surname>Steinberg</surname><given-names>KP</given-names></name><name><surname>Bernard</surname><given-names>GR</given-names></name></person-group><article-title>Recovery rate and prognosis in older persons who develop acute lung injury and the acute respiratory distress syndrome</article-title><source>Ann Intern Med</source><year>2002</year><volume>136</volume><fpage>25</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">11777361</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lagneau</surname><given-names>F</given-names></name><name><surname>D'honneur</surname><given-names>G</given-names></name><name><surname>Plaud</surname><given-names>B</given-names></name><name><surname>Mantz</surname><given-names>J</given-names></name><name><surname>Gillart</surname><given-names>T</given-names></name><name><surname>Duvaldestin</surname><given-names>P</given-names></name><name><surname>Marty</surname><given-names>J</given-names></name><name><surname>Clyti</surname><given-names>N</given-names></name><name><surname>Pourriat</surname><given-names>JL</given-names></name></person-group><article-title>A comparison of two depths of prolonged neuromuscular blockade induced by cisatracurium in mechanically ventilated critically ill patients</article-title><source>Intensive Care Med</source><year>2002</year><volume>28</volume><fpage>1735</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">12447516</pub-id><pub-id pub-id-type="doi">10.1007/s00134-002-1508-y</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Estenssoro</surname><given-names>E</given-names></name><name><surname>Dubin</surname><given-names>A</given-names></name><name><surname>Laffaire</surname><given-names>E</given-names></name><name><surname>Canales</surname><given-names>H</given-names></name><name><surname>Saenz</surname><given-names>G</given-names></name><name><surname>Moseinco</surname><given-names>M</given-names></name><name><surname>Pozo</surname><given-names>M</given-names></name><name><surname>Gomez</surname><given-names>A</given-names></name><name><surname>Baredes</surname><given-names>N</given-names></name><name><surname>Jannello</surname><given-names>G</given-names></name><name><surname>Osatnik</surname><given-names>J</given-names></name></person-group><article-title>Incidence, clinical course, and outcome in 217 patients with acute respiratory distress syndrome</article-title><source>Crit Care Med</source><year>2002</year><volume>30</volume><fpage>2450</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">12441753</pub-id><pub-id pub-id-type="doi">10.1097/00003246-200211000-00008</pub-id></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Luhr</surname><given-names>OR</given-names></name><name><surname>Antonsen</surname><given-names>K</given-names></name><name><surname>Karlsson</surname><given-names>M</given-names></name><name><surname>Aardal</surname><given-names>S</given-names></name><name><surname>Thorsteinsson</surname><given-names>A</given-names></name><name><surname>Frostell</surname><given-names>CG</given-names></name><name><surname>Bonde</surname><given-names>J</given-names></name></person-group><article-title>Incidence and mortality after acute respiratory failure and acute respiratory distress syndrome in Sweden, Denmark, and Iceland. The ARF Study Group</article-title><source>Am J Respir Crit Care Med</source><year>1999</year><volume>159</volume><fpage>1849</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">10351930</pub-id></citation></ref><ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>TA</given-names></name><name><surname>Rubenfeld</surname><given-names>GD</given-names></name><name><surname>Caldwell</surname><given-names>ES</given-names></name><name><surname>Hudson</surname><given-names>LD</given-names></name><name><surname>Steinberg</surname><given-names>KP</given-names></name></person-group><article-title>The effect of acute respiratory distress syndrome on long-term survival</article-title><source>Am J Respir Crit Care Med</source><year>1999</year><volume>160</volume><fpage>1838</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">10588594</pub-id></citation></ref><ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arroliga</surname><given-names>AC</given-names></name><name><surname>Ghamra</surname><given-names>ZW</given-names></name><name><surname>Perez Trepichio</surname><given-names>A</given-names></name><name><surname>Perez Trepichio</surname><given-names>P</given-names></name><name><surname>Komara</surname><given-names>JJ</given-names><suffix>Jr</suffix></name><name><surname>Smith</surname><given-names>A</given-names></name><name><surname>Wiedemann</surname><given-names>HP</given-names></name></person-group><article-title>Incidence of ARDS in an adult population of northeast Ohio</article-title><source>Chest</source><year>2002</year><volume>121</volume><fpage>1972</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">12065365</pub-id><pub-id pub-id-type="doi">10.1378/chest.121.6.1972</pub-id></citation></ref><ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reynolds</surname><given-names>HN</given-names></name><name><surname>McCunn</surname><given-names>M</given-names></name><name><surname>Borg</surname><given-names>U</given-names></name><name><surname>Habashi</surname><given-names>N</given-names></name><name><surname>Cottingham</surname><given-names>C</given-names></name><name><surname>Bar-Lavi</surname><given-names>Y</given-names></name></person-group><article-title>Acute respiratory distress syndrome: estimated incidence and mortality rate in a 5 million-person population base</article-title><source>Crit Care</source><year>1998</year><volume>2</volume><fpage>29</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">11056707</pub-id><pub-id pub-id-type="doi">10.1186/cc121</pub-id></citation></ref><ref id="B51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fialkow</surname><given-names>L</given-names></name><name><surname>Vieira</surname><given-names>SR</given-names></name><name><surname>Fernandes</surname><given-names>AK</given-names></name><name><surname>Silva</surname><given-names>DR</given-names></name><name><surname>Bozzetti</surname><given-names>MC</given-names></name></person-group><article-title>Acute lung injury and acute respiratory distress syndrome at the intensive care unit of a general university hospital in Brazil. An epidemiological study using the American-European Consensus Criteria</article-title><source>Intensive Care Med</source><year>2002</year><volume>28</volume><fpage>1644</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">12415455</pub-id><pub-id pub-id-type="doi">10.1007/s00134-002-1507-z</pub-id></citation></ref><ref id="B52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>PJ</given-names></name><name><surname>Quinn</surname><given-names>AC</given-names></name><name><surname>Grounds</surname><given-names>RM</given-names></name><name><surname>Hunter</surname><given-names>JM</given-names></name><name><surname>Boyd</surname><given-names>AH</given-names></name><name><surname>Eastwood</surname><given-names>NB</given-names></name><name><surname>Pollard</surname><given-names>BJ</given-names></name><name><surname>Pearson</surname><given-names>AJ</given-names></name><name><surname>Harper</surname><given-names>NJ</given-names></name><name><surname>Beale</surname><given-names>RJ</given-names></name><name><surname>Sutjarittam</surname><given-names>M</given-names></name><name><surname>Elliot</surname><given-names>JM</given-names></name><name><surname>Bion</surname><given-names>JF</given-names></name></person-group><article-title>A comparison of cisatracurium (51W89) and atracurium by infusion in critically ill patients</article-title><source>Crit Care Med</source><year>1997</year><volume>25</volume><fpage>1139</fpage><lpage>1142</lpage><pub-id pub-id-type="pmid">9233738</pub-id><pub-id pub-id-type="doi">10.1097/00003246-199707000-00013</pub-id></citation></ref><ref id="B53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rudis</surname><given-names>MI</given-names></name><name><surname>Sikora</surname><given-names>CA</given-names></name><name><surname>Angus</surname><given-names>E</given-names></name><name><surname>Peterson</surname><given-names>E</given-names></name><name><surname>Popovich</surname><given-names>J</given-names><suffix>Jr</suffix></name><name><surname>Hyzy</surname><given-names>R</given-names></name><name><surname>Zarowitz</surname><given-names>BJ</given-names></name></person-group><article-title>A prospective, randomized, controlled evaluation of peripheral nerve stimulation versus standard clinical dosing of neuromuscular blocking agents in critically ill patients</article-title><source>Crit Care Med</source><year>1997</year><volume>25</volume><fpage>575</fpage><lpage>583</lpage><pub-id pub-id-type="pmid">9142020</pub-id><pub-id pub-id-type="doi">10.1097/00003246-199704000-00005</pub-id></citation></ref><ref id="B54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kupfer</surname><given-names>Y</given-names></name><name><surname>Namba</surname><given-names>T</given-names></name><name><surname>Kaldawi</surname><given-names>E</given-names></name><name><surname>Tessler</surname><given-names>S</given-names></name></person-group><article-title>Prolonged weakness after long-term infusion of vecuronium bromide</article-title><source>Ann Intern Med</source><year>1992</year><volume>117</volume><fpage>484</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">1354426</pub-id></citation></ref><ref id="B55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Douglass</surname><given-names>JA</given-names></name><name><surname>Tuxen</surname><given-names>DV</given-names></name><name><surname>Horne</surname><given-names>M</given-names></name><name><surname>Scheinkestel</surname><given-names>CD</given-names></name><name><surname>Weinmann</surname><given-names>M</given-names></name><name><surname>Czarny</surname><given-names>D</given-names></name><name><surname>Bowes</surname><given-names>G</given-names></name></person-group><article-title>Myopathy in severe asthma</article-title><source>Am Rev Respir Dis</source><year>1992</year><volume>146</volume><fpage>517</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">1362636</pub-id></citation></ref><ref id="B56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Segredo</surname><given-names>V</given-names></name><name><surname>Caldwell</surname><given-names>JE</given-names></name><name><surname>Matthay</surname><given-names>MA</given-names></name><name><surname>Sharma</surname><given-names>ML</given-names></name><name><surname>Gruenke</surname><given-names>LD</given-names></name><name><surname>Miller</surname><given-names>RD</given-names></name></person-group><article-title>Persistent paralysis in critically ill patients after long-term administration of vecuronium</article-title><source>N Engl J Med</source><year>1992</year><volume>327</volume><fpage>524</fpage><lpage>528</lpage><pub-id pub-id-type="pmid">1353252</pub-id></citation></ref><ref id="B57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Lemos</surname><given-names>JM</given-names></name><name><surname>Carr</surname><given-names>RR</given-names></name><name><surname>Shalansky</surname><given-names>KF</given-names></name><name><surname>Bevan</surname><given-names>D</given-names></name><name><surname>Ronco</surname><given-names>JJ</given-names></name></person-group><article-title>Paralysis in the critically ill: Intermittent bolus pancuronium compared with continuous infusion</article-title><source>Crit Care Med</source><year>1999</year><volume>27</volume><fpage>2648</fpage><lpage>2655</lpage><pub-id pub-id-type="pmid">10628604</pub-id><pub-id pub-id-type="doi">10.1097/00003246-199912000-00007</pub-id></citation></ref><ref id="B58"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Khuenl-Brady</surname><given-names>KS</given-names></name><name><surname>Reitstatter</surname><given-names>B</given-names></name><name><surname>Schlager</surname><given-names>A</given-names></name><name><surname>Schreithofer</surname><given-names>D</given-names></name><name><surname>Luger</surname><given-names>T</given-names></name><name><surname>Seyr</surname><given-names>M</given-names></name><name><surname>Mutz</surname><given-names>N</given-names></name><name><surname>Agoston</surname><given-names>S</given-names></name></person-group><article-title>Long-term administration of pancuronium and pipecuronium in the intensive care unit</article-title><source>Anesth Analg</source><year>1994</year><volume>78</volume><fpage>1082</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">8198261</pub-id></citation></ref><ref id="B59"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leatherman</surname><given-names>JW</given-names></name><name><surname>Fluegel</surname><given-names>WL</given-names></name><name><surname>David</surname><given-names>WS</given-names></name><name><surname>Davies</surname><given-names>SF</given-names></name><name><surname>Iber</surname><given-names>C</given-names></name></person-group><article-title>Muscle weakness in mechanically ventilated patients with severe asthma</article-title><source>Am J Respir Crit Care Med</source><year>1996</year><volume>153</volume><fpage>1686</fpage><lpage>1690</lpage><pub-id pub-id-type="pmid">8630621</pub-id></citation></ref><ref id="B60"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coakley</surname><given-names>JH</given-names></name><name><surname>Nagendran</surname><given-names>K</given-names></name><name><surname>Yarwood</surname><given-names>GD</given-names></name><name><surname>Honavar</surname><given-names>M</given-names></name><name><surname>Hinds</surname><given-names>CJ</given-names></name></person-group><article-title>Patterns of neurophysiological abnormality in prolonged critical illness</article-title><source>Intensive Care Med</source><year>1998</year><volume>24</volume><fpage>801</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">9757924</pub-id><pub-id pub-id-type="doi">10.1007/s001340050669</pub-id></citation></ref><ref id="B61"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>MJ</given-names></name><name><surname>Coursin</surname><given-names>DB</given-names></name><name><surname>Scuderi</surname><given-names>PE</given-names></name><name><surname>Kamath</surname><given-names>G</given-names></name><name><surname>Prough</surname><given-names>DS</given-names></name><name><surname>Howard</surname><given-names>DM</given-names></name><name><surname>Abou-Donia</surname><given-names>MA</given-names></name></person-group><article-title>Double-blind, randomized, multicenter study of doxacurium vs. pancuronium in intensive care unit patients who require neuromuscular blocking agents</article-title><source>Crit Care Med</source><year>1995</year><volume>23</volume><fpage>450</fpage><lpage>458</lpage><pub-id pub-id-type="pmid">7874894</pub-id><pub-id pub-id-type="doi">10.1097/00003246-199503000-00007</pub-id></citation></ref><ref id="B62"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coakley</surname><given-names>JH</given-names></name><name><surname>Nagendran</surname><given-names>K</given-names></name><name><surname>Honavar</surname><given-names>M</given-names></name><name><surname>Hinds</surname><given-names>CJ</given-names></name></person-group><article-title>Preliminary observations on the neuromuscular abnormalities in patients with organ failure and sepsis</article-title><source>Intensive Care Med</source><year>1993</year><volume>19</volume><fpage>323</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">7755663</pub-id><pub-id pub-id-type="doi">10.1007/BF01694705</pub-id></citation></ref></ref-list></back></article>